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ABSTRACT  
 This dissertation examined the relationship between the predictor variables 
of adolescent refusal self-efficacy, social capital, and the common liability to addiction 
and the outcome variable of continuing care choices. Using a sample of 71 adolescents 
who had attended The CASTLE, High Point treatment center’s adolescent center in 2011, 
evidence was found to support the relationship between refusal self-efficacy, social 
capital and these outcomes. Following the results of preliminary analyses, family history 
of drug use was included in the list of predictor variables examined, in relation to the 
outcome of adolescent continuing care choices. It was determined that refusal self-
efficacy and social capital were related to outcome choices of adolescents during 
treatment. Furthermore, including the independent variables of family history of drug use 
and common liability to addiction provided a more robust display of the directions 
adolescents moved towards.  
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GLOSSARY  
Abstinence: voluntary forbearance of substance use e.g. alcohol or drugs.  
Abuse: utilization of substances or medications in a way outside of their intended or 
prescribed uses to achieve an altered state.  
Adolescence: The developmental period distinguished by a transition from family-
oriented state of childhood to the independent, more peer-driven state of 
adulthood. For this study, I will focus on the ages 13–18. 
Addiction: according to the American Society for Addiction Medicine (2011) addiction 
is a chronic, relapsing brain disease that is characterized by compulsive drug 
seeking and use, despite harmful consequences; also referred to as substance-use 
disorder.  
Common-Liability to Addiction: according to (Vanyukov, Tarter, & Kirillova, Kirisci, 
Reynolds, Kreek, Conway, Maher, Iacono, Bierut, Neale, Clark, and Ridenour 
2012) the CLA represents the underlying phenotypic traits that indicate a non-
specific liability to all drug addictions regardless of the order of initiation.  
Dependence: according to the American Society for Addiction Medicine (2011) 
dependence is a biological adaptation to drug action, occurring separate from drug 
abuse as in pain treatment.  
Liability: the underlying sequence of attributes immediately related to the grade of traits 
not inherited in the same way as single-gene or monogenic traits, but nonetheless 
demonstrate predictable familial distribution (Vanyukov et al., 2012).  
  xv 
Phenotype: the set of observable characteristics of an individual resulting from the 
interaction of its genotype with the environment (Vanyukov et al., 2012).  
Pre-frontal Cortex: according to Merriam’s dictionary the prefrontal cortex is the gray 
matter of the anterior part of the frontal lobe that is highly developed in humans 
and plays a role in the regulation of complex cognitive, emotional, and behavioral 
functioning 
Self-Efficacy: Psychologist Albert Bandura has defined self-efficacy as one's belief in 
one's ability to succeed in specific situations or accomplish a task.  
Social Capital: according to Hser, Longshore and Anglin, (2007) social capital 
represents the networks of relationships among people who live in a particular 
society that allow for connectedness.  
Substance Use Disorder: According to The National Center on Addiction and Substance 
Abuse. (2012), substance use disorder occurs when a person's use of alcohol or 
another substance (drug) leads to health issues or problems at work, school, or 
home  
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CHAPTER ONE: INTRODUCTION 
 Adolescent substance use, America’s foremost health problem, is currently 
increasing (The National Center on Addiction and Substance Abuse, 2011) with 48% of 
students using illicit drugs by the time they leave high school (Johnston, O’malley, 
Bachman, & Schulenberg, 2011). While 30 years ago most cases of teen death were 
attributed to natural causes i.e. disease or illness (Haynie, Soller, & Williams, 2014), 
most teen deaths today are connected to preventable behaviors, unhealthy environments, 
and risky decisions such as substance use initiated during adolescence (Gutierrez, 2015). 
With nine out of 10 addicted adults reporting that their substance use began in 
adolescence (The National Center on Addiction and Substance Abuse, 2011), substance 
use disorder remains the greatest preventable cause of death (Johnston, O’malley, 
Bachman, & Schulenberg, 2013).  
 The developmental experiences adolescents face, alongside the physical, 
neurological, and hormonal changes culminating during this period, initiate a window of 
vulnerability to addiction (Feinstein, Richter, & Foster, 2012), making this a critical but 
difficult time to intervene (Guerrini, Quadri, & Thomson, 2014; Karmiloff-Smith, Casey, 
Massand, Tomalski, & Thomas, 2014). Addiction is by nature related to degradation and 
crime, demanding immense sacrifice from individuals, families, and society (Vanyukov, 
Kirisci, Tarter, Simkevitz, , Kirillova, Maher, & Clark, 2003a). The increasing economic, 
social, and emotional demands adolescent substance use places on public health resources 
make its reduction one of our nation’s highest public health priorities (Koh, 2010). To 
this end, it is imperative that researchers identify more constructs associated with 
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decreasing levels of adolescent substance use (Choi, Krieger, & Hecht, 2013).  
 The purpose of the current study is to examine the effect of the continuous 
variable of the Common Liability to Addiction (CLA) in a treatment-seeking adolescent 
population. Specifically, this study seeks to explore how self-efficacy and social capital 
might interact in relation to the CLA phenotypes, to determine any correlation exists with 
treatment outcome decisions.  
Addiction and Adolescence  
 The American Society of Addiction Medicine (ASAM) has classified addiction as 
a progressive, relapsing, brain disease (2011), and research has definitively linked 
substance use with lasting physical changes occurring in the structure and function of 
brain circuitry (Volkow, Wang, Tomasi, & Baler, 2013; Volkow, Wang, Tomasi, & 
Telang, 2010; Lüscher & Malenka, 2011). Studies estimate that between two-thirds and 
four-fifths of both adults and adolescents begin using again in the 6 months after an 
episode of drug or alcohol treatment (Brown, D'Amico, McCarthy, & Tapert, 2001; 
Brown, Vik, & Creamer, 1989; Cornelius, Maisto, Pollock, Martin, Salloum, Lynch, & 
Clark, 2003; Hunt, Barnett, & Branch, 1971), and neuroimaging has verified that 
addiction to illicit substances substantially affects the structures necessary for memory, 
attention, cognitive control, and judgment (Feinstein et al., 2012). This additional 
research confirms that substance use and withdrawal impair these brain regulation 
systems, which creates the neural basis for the hallmark of addiction—persistent 
substance use despite serious adverse consequences (Belin, Belin-Rauscent, Murray, 
Everitt, 2013; Koob, 2013; Volkow, Wang, Tomasi, & Telang, 2011).  
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 As devastating as addiction can be for adults, it is a particularly daunting obstacle 
for youth. Adolescence is the key developmental period in the life span during which 
behavior patterns initiate and trajectories of health and well-being are first established 
(Furstenberg, 2000). Youth who initiate substance use during this time alter the primary 
formation of the regulatory processes and systems of control naturally occurring in their 
developing neural networks, multiplying the effects of substance use (Casey, 2010; Luna, 
Padmanabhan, & O’Hearn, 2010; Rutherford, Mayes, & Potenza, 2010). In fact, one in 
four Americans who begin using any psychoactive substance before age 18 become 
addicted, compared with one in twenty-five Americans who start using over the age of 21 
(The National Center on Addiction and Substance Abuse, 2011). Thus, 1.7 million 
adolescents between 12 and 17 years of age develop addictions each year (The National 
Center on Addiction and Substance Abuse, 2012).  
 Adolescents experience a process of growth in progressive stages beginning with 
the onset of puberty and extending until about 25 years of age, which exposes them to 
new levels of hormones, neurotransmitters, and endorphins (Spear, 2000). While 
stimulating important brain growth, cognitive abilities, muscle growth, and social drives, 
this change proceeds in a stunted, uneven fashion, resulting in behaviors that are 
unexplainable even to the teen performing them. The ensuing pubescent phase 
dramatically becomes more confounding as youth experience heightened societal 
expectations and responsibilities (Steinberg, 2010). The number one predictor for 
adolescent substance use initiation is substance-using friends (Jackson, 1997; Monahan, 
Steinberg, & Cauffman, 2009; Wills & Cleary, 1999) and this period of disproportionate 
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physical, and psychological reactions are when peers assume the roles of highest 
importance (Burnett, Sebastian, Kadosh, & Blakemore, 2011). With greater peer 
affiliation, it is normative that youth should begin their process of compelled exploration, 
trying on different identities as they transition to adulthood (Chein, Albert, O’Brien, 
Uckert, & Steinberg, 2011; Erikson, 1968; Spear, 2011; Spear, 2000).  
 These patterns of behavior during adolescence, i.e. the prominence of peer-driven 
actions, pleasure-seeking, and risky behaviors in respect to children and adults have been 
witnessed across a variety of mammalian species (Chambers, Taylor, & Potenza, 2003; 
Forbes, & Dahl, 2010; Spear & Varlinskaya, 2010). Neuroimaging techniques only just 
developed during the last two decades have revealed that the prefrontal cortex, the area 
responsible for executive function and age-related social and cognitive maturation, is the 
last area of the brain to mature (Steinberg, 2005). This bottom-up process of brain 
development during this period, was initially thought to be the reason for the impulsivity, 
poor decision-making, and elevated drug use often seen in adolescence (Ernst, Romeo, & 
Andersen, 2009; Tarter, 2002).  
 However, additional imaging studies reveal that this is only part of the story. 
Brain maturation has been observed in neuroimaging as a reduction of the grey matter 
most prominent in childhood, as the increasingly sophisticated growth of white matter 
during adolescence, and early adulthood replaces it (Giedd et al., 1999). As the pre-
frontal cortex is developing, it is becoming optimized. Intra-cortical connections between 
pre-frontal areas and interior areas of the brain become more pronounced (Spear, 2000) 
and are reinforced through learning and behavior, to facilitate development in the areas 
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that correspond with improvements in memory, attention, and cognition (Steinberg, 
2005) creating the more immediate and accurate interactions needed for adulthood.  
 These processes also involve pruning, the selective elimination of inefficient 
neural connections based on experience (Steinberg, 2008), and myelination, the layering 
of myelin on neurons to propagate more efficient action potentials (Chambers et al., 
2003). This produces an optimization period as the brain, guided by experience and 
feedback, is streamlined to become more efficient, interacting and responding holistically 
to the world around it (Chambers et al., 2003; Somerville et al., 2013; Spear, 2013). Thus, 
adolescence, a period when motivational reactivity overtakes rational control, seeking 
high-risk choices, and immediate rewards over long-term concerns (Steinberg, 2008) 
have been evolutionarily conserved to facilitate the most adaptive transition to human 
adulthood (Spear, 2011). Although it results in the increased death rates observed among 
teenagers (Doremus-Fitzwater, Varlinskaya, & Spear, 2010; Murphy, Xu, & Kochanek, 
2013; Ozer, Macdonald, & Irwin, 2002; Resnick et al., 1997), the resultant effect is 
separation from the herd and independent capable adaptation (Spear, 2000).  
 The sudden force of the complex genetic, biological, and hormonal interactions 
can overwhelm adolescents, predisposing many to engage in substance use. For 
adolescents, developmentally immature executive functions, with increased impulsivity, 
and sensation-seeking may make experimenting with alcohol and drugs appear to some 
extent a normative behavior (Pokhrel et al., 2013). However, addiction is always context-
dependent (Guerrini et al., 2014). Social contexts often encourage substance use disorders 
(SUDs) and addiction. Among youth, substance use among friends, along with other peer 
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influences, remain the strongest predictors of alcohol use (Osgood, Feinberg, Wallace, & 
Moody, 2014), illicit drug use, and addiction (Ramirez, Hinman, Sterling, Weisner, & 
Campbell, 2012; Van Ryzin, Fosco, & Dishion, 2012).  
 During the adolescent stage of transition, adolescents are especially susceptible. 
Emotional vulnerability to outside influences such as peer pressure, friends, and 
environment compels adolescents to take risks they would avoid on their own (Albert et 
al., 2013; Chein, Albert, O’Brien, Uckert, & Steinberg, 2011). They have greater 
biological sensitivity, too, as psychoactive substances present more toxic effects on the 
raw, emerging, still developing brain matter (Rutherford et al., 2010; Spear & 
Varlinskaya, 2010). This multiplies the effects of the drugs, stimulating a faster, more 
intense response and a deeper addiction (Rutherford et al., 2010).  
 It is well known that the severity of changes in the brain’s structure and function 
is recursive and perpetuated by the changed behavioral patterns, friends, and 
environments, present in addiction (Lisdahl, Wright, Medina-Kirchner, Maple, & 
Shollenbarger, 2014). The combination of aberrant behavior patterns and changed social 
structures are reinforced by the effect of the substances, which create, then preserve, the 
increasingly severe consequences represented by the continuum of substance use disorder 
(American Psychiatric Association, 2013). The pandemic overdose death crisis occurring 
in Massachusetts demonstrates how, ultimately, adolescents consolidate their identity 
with addiction as they transition to adulthood (Kirillova, Vanyukov, Kirisci, & Reynolds, 
2008; Tarter, Kirisci, Ridenour, & Bogen, 2012).  
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Complications of Treatment  
 Despite similar brain processes during addiction in adults and youth, there are 
significant clinical differences complicating treatment efforts necessitating concentrated 
attention from treatment providers (McKay et al., 2009; Winters, 2014). Compared with 
adults, adolescents more often present to treatment as poly-drug users, tend not to reveal 
withdrawal symptoms, and can also be experiencing serious problems while still not 
meeting official diagnostic criteria for addiction (Winters et al., 2014). Additionally, 
youth are more ambivalent about stopping their substance use and less likely than adults 
to seek treatment on their own, showing less insight, more denial, and typically 
experience fewer health problems from using (Chung & Maisto, 2009; Kelly, Finney, & 
Moos, 2005; Winters et al., 2014).  
 Developmental, psychological, and neurological evidence clearly demonstrates 
evidence for adolescent susceptibility for initiating substance use (Albert et al., 2013; 
Spear, 2011), and it has been shown that once substance use is in place, treatment and 
recovery can be an arduous and difficult process as adolescents relapse with greater 
frequency after treatment than adults do (Dennis, Scott, & Funk, 2003; Dennis, Scott, 
Funk, & Foss, 2005; Scott et al., 2005; Scott & Dennis, 2009; Winters et al., 2014). 
Pharmacological, behavioral, and genetic research has further shown that the effects of 
substance use are cumulative, that they are most pernicious when occurring early in life, 
and that significant and long-lasting effects from substance use can occur even from 
relatively low levels of use (McLellan, Lewis, O’Brien, & Kleber, 2013). Addiction 
plagues the adolescent brain with impaired cognition, memory problems, intellectual 
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deficiencies, and can embed triggers during development that threaten, and will relapse 
even years after remission (Somerville, Hare, & Casey, 2011; Winters et al., 2014).  
 Another consideration is the time-sensitive nature of development. 
Epidemiological research reveals that about one third of psychiatric disorders are 
attributable to negative childhood experiences (Keyes et al., 2012), and substance use 
frequently arises. However, this then impedes adolescent age-linked milestones, as the 
toxicity of substances interfere with the course of brain growth and age-related 
accomplishments, possibly contributing to later or co-occurring psychiatric disorders 
(Center for Substance Abuse Treatment, 2005; Squeglia, Jacobus, & Tapert, 2009). 
Among adolescents, addictions and psychiatric disorders correlate in a bidirectional 
manner, with each increasing the risk for the other (Essau, 2011). Many studies 
demonstrate increased incidence of psychiatric illness associated with adolescent use of 
marijuana (Guidali et al., 2011; Kuepper et al., 2011), which is currently the most widely 
used illicit drug among adolescents (Johnston, O’malley, & Bachman, 1999; Wittchen et 
al., 2009).   
 Substance abuse treatment is designed to target the symptoms and psychosocial 
deficits presumed to underlie the disorder (Khazantian, 1985). Treatment also seeks to 
enhance patient beliefs of self-efficacy by improving perceptions that they can achieve 
and sustain changed behaviors in risky situations and difficult domains (Witkiewitz & 
Marlatt, 2004). Adult outcome findings have shown congruencies in adolescent 
populations, with research demonstrating that generally positive outcomes increase 
linearly with length of time spent consistently in treatment, and thresholds of vast 
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improvement between 21 and 90 days (Friedman, Glickman, & Morrissey, 1986; Dennis, 
2002; Hser et al., 2001). Despite these benefits, adolescents often resist and underutilize 
treatment (Maisto, Chung, Cornelius, & Martin, 2003; Substance Abuse and Mental 
Health Services Administration, 2008). Teenagers will often only enter treatment because 
parents, schools, or courts have insisted that they do so (Baer & Peterson, 2004; Baer & 
Peterson, 2002; Maisto et al., 2003).  
 Elucidation of the mechanisms through which treatment interventions can affect 
changes in health and behavior is a recognized priority for clinical research (National 
Institute for Health, 2016; Willenbring, 2010). Because of the significant association 
between better outcomes and retention in treatment (Laudet, 2009; Simpson, 2004; 
Stevens et al., 2014; Vanderplasschen et al., 2013; Zhang, Friedmann, & Gerstein, 2003), 
it is important for researchers to continue identifying potential mechanisms of change, to 
understand what and why treatment works, and provide the necessary knowledge to help 
develop more effective treatments (Laudet, 2009).  
 It is generally known that adolescents are more averse to treatment than adults 
because they are less likely to have experienced more severe consequences from their 
substance use (Maisto et al., 2003; Brown et al., 2001). In addition, youth are more 
developmentally vulnerable, and more susceptible to the influences of peers (Tanner-
Smith, Wilson, & Lipsey, 2013). Developmental research indicates that peer deviancy is 
associated with ensuing increases in substance use, delinquency, and violence, as well as 
adjustment difficulties in adulthood (Connell, Gilreath, Aklin, & Brex, 2010; Dishion, 
McCord, & Poulin, 1999). Unfortunately, for these reasons, multiple treatment episodes 
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over a “treatment career” are commonplace among adolescents (Hser, Anglin, Grella, 
Longshore, & Prendergast, 1997; McLellan, Lewis, O’Brien, & Kleber, 2000; Dennis et 
al., 2005; M. Dennis, 2007), with a minimum of three to four inpatient admissions over 
an eight-year period before sustained abstinence of one year is achieved (Godley et al., 
2014).  
 Research shows that risk of relapse is particularly problematic in the first three 
years of abstinence and may never completely go away, suggesting the need for 
promoting strategies and programs that support the long-term management of recovery 
(Dennis et al., 2007). While retention in treatment has been associated with positive 
outcomes in both adult and adolescent treatment studies, there is concern that repeated 
exposure to the negative peer groups most likely found in acute treatment programs, 
could have a threshold for negative returns. Research has shown the significant influence 
on adolescents by their peers in treatment, and in fact, many leave addiction treatments in 
groups of two or more (Albert et al., 2013; Dishion et al., 1999; Hser et al., 2001). 
Combining the developmental and intervention research builds a case, then, for locating 
causal connections between peer environments and an escalation in problem behavior in 
early adolescence (Dishion, Véronneau, & Myers, 2010).  
 Across a range of adolescent SUD treatment approaches—residential, short-term 
inpatient and outpatient—drug-free longer stays in treatment (90 days or more) have been 
associated with lower levels of alcohol and drug use and lower rates of arrest during the 
year after treatment (Orlando, Chan, & Morral, 2003). Troubled youth with peer groups 
characterized by greater levels of crime, violence, and substance use are particularly at 
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increased risk for ending treatment too soon (Hser et al., 2001; Orlando et al., 2003). 
Adolescents are especially vulnerable after treatment when returning to situations among 
old friends, or at school, where previous thought processes can often trigger substance 
use (Humphreys, Moos, & Cohen, 1997; Schutte Byrne, Brennan, & Moos, 2001; Scott, 
2005).  
 Motivational Interviewing, a thoroughly established evidence-based practice 
frequently used in treatment centers, conceptualizes change on a continuum. This 
perspective and its accompanying motivational interviewing style has shown itself to be 
effective by helping clinicians patiently understand their patients’ resistance, as well as 
helping the patients recognize and understand it themselves (Khantzian, 2012). As 
change is ongoing, enduring, and inevitable, these perspectives allow clinicians to “roll” 
with resistant adolescents, mirroring responses, and providing feedback that helps them 
recognize and process their own ambivalence (Miller & Rollnick, 2002).  
 A psychodynamic perspective suggests that addiction is primarily a disorder of 
self-regulation, and that individuals with addictions suffer because they either cannot or 
do not control their emotions, self-esteem, and relationships, and similarly they cannot or 
do not regulate their behavior (Khantzian, 2012). Neurological studies appear to validate 
this perspective, demonstrating that the inhibition control areas and circuitry in 
individuals with addiction appear less connected, damaged, or underdeveloped (Goldstein 
& Volkow, 2002; Koob & Volkow, 2010; Ersche et al., 2013). The delayed executive 
functioning skills connected with this slow growth makes adolescence a vulnerable 
period (Ernst, Romeo, & Andersen, 2009; Geier & Luna, 2009; Spear, 2011; Albert et al., 
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2013), and the thrill-seeking behaviors and new environments expose young people to 
greater risk for addiction and places where substance and alcohol use are common. 
During this time, peer conformity and concerns about social acceptance are at their peak. 
Anxiety about how their peers see them can foster an intense desire to belong. This can 
influence younger adolescents to go along with activities in which they would otherwise 
not engage (Micucci, 1998). The developmental, neural imbalances during this stage may 
also further advance additive effects on their natural impulsivity, as well as increased 
sensitivity to rewards (Dick, Aliev, Viken, Kaprio, & Rose, 2010; Guerrini et al., 2014; 
Marshall, 2014).  
 Structural brain abnormalities in the prefrontal cortex have been linked to impulse 
control disorders and correlated with cognitive dysfunction in many substance users 
(Clark, Robbins, Ersche, & Sahakian, 2006; Clark, Roiser, Robbins, & Sahakian, 2009; 
Lisdahl et al., 2014; London, Ernst, Grant, Bonson, & Weinstein, 2000). As features of 
the brain (Peper et al., 2007; Thompson et al., 2001; Thompson et al., 2004) and 
addiction (Agrawal & Lynskey, 2008; Li & Burmeister, 2009; Uhl et al., 2008) are both 
known to be heritable, it is possible some users may differ in brain structure before they 
even begin drug use, which may be linked to a genetic vulnerability (Ersche et al., 2013). 
Such knowledge could be a powerful tool for patients actualizing the opportunity 
addiction treatment offer for changing behaviors. Clinicians have a unique opportunity to 
help patients develop a drug-free lifestyle and then maintain abstinence (Prochaska, 
DiClemente, & Norcross, 1992) through collaborating with adolescent patients to 
negotiate changeable attitudes and behaviors—to create sustainable abstinence 
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(Prochaska, 2013). However, this can be very difficult for adolescents to process, and it is 
established that youth at varying developmental stages will present unique clinical 
challenges (Ingersoll, Wagner, & Gharib, 2000; Miller & Rollnick, 2002).  
 Residential treatment protects youth from the negative influences and patterns 
substances have exposed them to, allowing them to develop greater coping behaviors and 
self-efficacy beliefs along with practical skills in these areas. However, even among 
adolescents who completed inpatient residential treatment, as many as 79% returned to 
substance use by the one-year follow up (Brown, Tapert, Tate, & Abrantes, 2000; 
Tomlinson, Brown, & Abrantes, 2004). This is likely due to the greater influence of peers 
at this developmental stage (Albert et al., 2013). Immaturities in functional integration of 
the neural signals between cortical hubs likely challenge the adolescent’s ability to 
negotiate social, emotional, and cognitive factors simultaneously (Luna et al., 2010). 
Research with adolescent responses to social cues show an exaggerated, over response, 
and heightened neural activation to positive social cues such as facial expressions and 
positive feedback (Pfeifer et al., 2011).  
 The self-regulation difficulties and heightened reactions that typify adolescent 
behaviors do, however, show individual variances (Rothbart & Posner, 2006; Stroufe, 
1997). The implication of differences indicates that some of these behaviors may be 
moderated. However, this will necessitate increasingly personalized care to create more 
distinctive and individual-specific responses to treatment than currently exist (Tarter et 
al., 2012). Research shows that development contains a near-infinite multiplicity of 
interactions, all influenced by unique environments and differing biological makeups. 
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This complex, ever-evolving interplay shapes reactions, choices, and opportunities 
(Karmiloff-Smith et al., 2014; Tarantino et al., 2014). The intricacy of this process in 
adolescents require developmentally-informed interventions that are distinct from 
methods used with adults (Karmiloff-Smith et al., 2014; Spear, 2011; Wisdom & Gogel, 
2010), necessitating flexibility to identify promising areas for intervention (Casey & 
Jones, 2010).  
 Psychological, cultural, and, biological perspectives are uncovering the biology of 
cognitive and behavioral processes that sabotage and compromise individual capacity for 
positive personal choices. Unfortunately, because of the pleasurably reinforcing attributes 
of addictive substances, and the physiological and psychological reinforcing attributes 
they bring about, adolescents often refuse to acknowledge addiction problems or seek 
treatment (Maisto et al., 2003). The nature of substances to alter the physiology of 
capacity (Meier et al., 2012) may also indicate that there is in fact a point of no return, 
making treatment essential for adolescents.  
 Recent genetic, neurological, and psychological understandings afford prime 
opportunities to approach this problem in novel ways (Tarter et al., 2012; Vanyukov, et 
al., 2012; Hicks, Iacono, & McGue, 2012). Fresh perspectives with new findings may 
help identify more specific targets during treatment, implement tools for assessing these 
targets (i.e. new self-report lenses with behavioral, neurocognitive/neural measures), and 
identify clinically relevant differences useful to guide the selections of therapies (Riggs et 
al., 2007; Potenza, Sofuoglu, Carroll, & Rounsaville, 2011; Steinberg, 2010).  
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The Common Liability to Addiction  
 Adolescent addiction is proving to be expansive, problematic, and costly. The 
increasing need for an assessment of the risk for addictions (Conway et al., 2010) led the 
Center for Education and Drug Abuse Research (CEDAR) to develop the transmission 
liability to addiction indices which identify a common liability to addiction [CLA] 
(Vanyukov et al., 2009; Kirisci et al., 2009) through a catalogue of symptoms currently 
known to be phenotypes; genetic behavioral characteristics.  
 It has long been known that alcoholism and addictive disorders run in families 
(Kirisci et al., 2012). Large national and international epidemiological surveys 
(Degenhardt et al., 2010; Johnston et al., 2011; Abuse, 2014) demonstrate that high 
comorbidity of substance use and other disorders occur at rates higher than can be 
expected by chance (Palmer et al., 2012). The original common liability to addiction 
index developed by CEDAR used 45 questions and has accurately predicted addiction up 
to 12 years later (Kirisci et al., 2009; Vanyukov et al., 2009). Having proved to be more 
accurate than examining parental drug abuse alone, this index can provide an accurate 
estimate of heritable risk even in the absence of any parental data, to correctly predict an 
individual’s addiction by early adulthood (Hicks et al., 2012; Vanyukov et al., 2009).  
 For liabilities to behavioral disorders such as substance use for which there is no 
definitive consensus regarding what is considered normal versus pathological, the 
diagnoses for substance use disorder are identified using the medical standards of current 
behavioral health providers. Commonly, the American Society for Addiction Medicine 
(ASAM) patient placement guidelines (2001) and the Diagnostic Statistical Manual Fifth 
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Version (DSM V), produced by the American Psychiatric Association (2013 ), are 
utilized by insurance companies and practitioners to categorize the severity of addictions. 
Unfortunately, diagnosis involves hundreds of different possible combinations, and the 
inclusion of over 10 different drug classes, making the DSM a general tool for research, 
with little to no predictive capability (Vanyukov et al., 2012). The CLA, however, 
contains behavioral-genetic traits that are evidenced by specific behavior sets long 
correlated with addiction (Vanyukov et al., 2009; Vanyukov et al., 2003a; Vanyukov et 
al., 2003b; Vanyukov et al., 2012; Palmer et al., 2012; Hicks et al., 2012), and have 
demonstrated reliable predictive ability within numerous cohorts (Arria, Vincent, & 
Cadeira, 2009; Hicks et al., 2012; Kirisci et al., 2009; Vanyukov et al., 2009).  
 The continuous development and exploration of the CLA by CEDAR researchers 
and others has revealed much about the nature of addiction. This research demonstrates 
that a common liability does in fact appear in the development of addiction, and that the 
CLA can be utilized to measure it. This index measures the continuous trait of addiction 
through identification of non-substance-using characteristics that indicate underlying 
genetic traits such as depression or impulsivity. The CLA characteristics have established 
accurate validity to identify liability without further genetic information or knowledge of 
family history.  
 Studies utilizing these methods with similar questions and extant data sets 
demonstrate that this method also has validity in predicting future substance abuse, 
confirming that the variance was genetic—not influenced by environmental differences—
and showing no gender differences. Computer adaptive testing has shown the consistency 
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of this methodology, as well as paring down the assessment methodology, for reducing 
the amount of testing time, which can allow quicker screenings and make them available 
for more people. Kirisici et al.’s (2013) study revealed that the highest CLA scores were 
only present for those that developed addiction. As the length of time and addiction 
progressed, the CLA scores dramatically increased, while the scores for the non-addicted 
cohorts either stayed the same or decreased. In other words, addiction appeared to 
correspond with index indicators within only a particular subset of the sample, while the 
other participants demonstrated the presence of the same or reduced index measures 
(Kirisci et al., 2013). These studies revealed that externalizing disinhibition, while not the 
only indicator, was enough of a factor to categorize those with the common liability to 
addiction, generally, as being socially deviant, and the research conducted with young 
adults ultimately revealed the need for further research with younger populations.  
Self-Efficacy  
 Identified as a necessary component of change (Nigg & Courneya, 1998), the self-
efficacy construct has long been readily applied in the study and treatment of addictive 
behaviors. Treatments have been shown to be effective in addressing adolescent 
addictions (Winters, Botzet, & Fahnhorst, 2011). The problem, however, is that research 
into implementing components of change into treatment with adolescents is still limited 
(Kadden & Litt, 2011). Across therapeutic modalities, substance abuse interventions 
commonly seek to enhance patients’ motivation to change their substance use behavior, 
increasing confidence in their ability to achieve and maintain the change, and to impart or 
bolster coping skills, encouraging their ability to manage high-risk situations (Finney, 
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Noyes, Coutts, & Moos, 1998; Morgenstern, Labouvie, McCrady, Kahler, & Frey, 1997). 
Since adaptation, growth, and change are literally what define the adolescent period in 
pursuit of adult identity formation (Stroufe, 1997), this could be the most critical time of 
life for securing lasting, sustainable change.  
 Bandura (1977) defines self-efficacy as a person’s belief about one’s own ability 
to produce levels of performance to influence attainment in life. An individual’s level of 
self-efficacy helps determine how they think, feel, and motivate themselves, as well as 
how they behave (1997). Bandura conceptualized efficacy expectancy as the belief that 
one can perform a certain behavior to produce a desired outcome. Self-efficacy beliefs 
are known to operate across a diverse sphere of behavioral functions such as work-related 
performance, academic performance, psychosocial functioning, and health functioning 
(1986). Bandura and Locke (2003) demonstrated self-efficacy to be a strong predictor of 
coping, level of performance, and perseverance in the face of difficulty.  
 The initial research on efficacy and addiction was conducted using cigarette 
smokers attempting to quit, and individuals working to control their alcohol use and other 
addictive behaviors (Annis & Davis, 1988; Prochaska & DiClemente, 1986; DiClemente, 
Carbonari, Montgomery, & Hughes, 1994; DiClemente, Fairhurst, & Piotrowski, 1995; 
Condiotte & Lichtenstein, 1981; Rollnick & Heather, 1982; Yates & Thain, 1985). 
Although efficacy has become one of the most consistent outcome indicators to date 
(Ilgen et al., 2005), the study of self-efficacy in adolescent substance abuse disorders is 
still limited (Burleson & Kaminer, 2005), and little attention has been paid to the role of 
moderating variables (Kadden & Litt, 2011).  
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 In studies of adults, ratings of self-efficacy have been found to predict drinking 
behavior (Annis & Davis, 1989; Maisto, McKay, & O'Farrell, 1998). Prochaska et al. 
(1992) found that in adult smokers, people in an active state of change reported higher 
levels of self-liberation or willpower. They began to determine and choose the actions in 
which they wanted to participate, and implemented self-control in a variety of situations. 
People with higher self-efficacy believed they had the power and ability to change in 
major ways. Accordingly, efficacy in coping with situations that may typically lead to 
drug use reduces the risk of returning to substances (Marlatt & Gordon, 1985). Efficacy 
has also been found to be a relevant concept with adolescents in outpatient treatment 
settings, establishing that the higher the self-efficacy belief, the more likely the 
subsequent abstinence (Burleson & Kaminer, 2005). Thus, it appears that positive self-
efficacy is associated not only with higher rates of abstinence, but also with more positive 
outcomes regardless of the SUD treatment conditions.  
 Bandura (1999) established that people with higher self-efficacy would benefit 
more from additional substance addiction treatment. Results evaluating the influences of 
discharge status and during-treatment change among young adults suggest that self-
efficacy is an important predictor of short-term sobriety outcomes (Kelly, Daley, & 
Douaihy, 2012). Self-efficacy measured at various points over treatment has also been 
consistently associated with sobriety outcomes (Adamson, Sellman, & Frampton, 2009; 
DiClemente, Marinilli, Singh, & Bellino, 2001; McKay, 2001; Morgenstern et al., 1997; 
PMRG, 1997). Thus, evidence suggests that self-efficacy represents a clinically 
meaningful summary indicator for monitoring progress and potential during early 
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recovery.  
 Treatment for adolescents with substance-use disorder often concentrates on 
enhancing youths’ perceptions of their self-efficacy to resist substances and manage 
behavior in substance-infused situations. Drug-refusal self-efficacy has proven to be a 
moderator of both environmental influence and behavior (Maisto, Carey, & Bradizza, 
1999). Self-efficacy as a predictor variable has remained consistent among studies despite 
class of substance or population.  
 With teenagers, the most often-reported drug adolescents enter treatment for is 
marijuana, and refusal self-efficacy has demonstrated to be one of the strongest and most 
consistent predictors of future marijuana use in trials for adult marijuana users (Litt, 
Kadden, & Stephens, 2005). However, this can be confusing; while self-efficacy is 
considered a positive predictor, many patients in treatment are not completely motivated, 
or in a position yet to view themselves or their lives positively. Schell, Orlando, and 
Morral (2005) found that the higher the perceived efficacy, the lower the transition to 
further treatment among adolescents. Despite the known efficacy of continuing treatment, 
this makes sense for adolescents as they have not yet established cognitive maturity, and 
their regulation systems are still under the effects of emotions rather than reason 
(Steinberg, 2005). Thus, the more certain they feel about their ability to change, the less 
likely they will feel any need to attend further treatment.  
 Walker, Neighbors, Rodriguez, Stephens, & Roffman (2011) examined the effects 
of perceptions and self-efficacy on marijuana use outcomes, to understand the factors that 
influence adolescent substance abuse. They found that drug refusal self-efficacy was 
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negatively associated with negative outcomes. Drug refusal self-efficacy was associated 
with reductions in frequency of use, controlling use, and reducing the temptation to use. 
It was also found that marijuana use promoted associating with others who smoke more 
and approve more of marijuana smoking. Thus, it was suggested (2011) suggested that 
self-efficacy might be influenced by the peer network rather than individual beliefs. This 
supports the premise of utilizing further residential treatment after stabilization inpatient 
treatment to control for peer affiliation and enable the continued development of self-
efficacy beliefs and self-regulatory skills.  
What we can establish from the plethora of research is that despite numerous co-
occurring and complicating factors involved during adolescent addiction treatment, it has 
been definitively established that both self-efficacy and further treatment result in more 
positive outcomes (Trent, 1998; Ouimette, Moos, & Finney, 1998; Hser et al., 2001; 
Stein, Deberard, & Homan, 2013; Winters et al., 2014). Yet, adolescents relapse at higher 
than ever rates, demonstrating that it is still unknown why certain treatments work better 
for some and not others, or how to increase gains for more adolescents across the 
continuum of care (Wills, Pokhrel, Morehouse, & Fenster, 2011).  
Social Capital  
 Research has established the validity of studying self-efficacy as an outcome 
variable, however some of the results are mixed (Kadden & Litt, 2011). We know that 
developing adolescents are often under the effect of peer influence and as a result this 
moderates self-efficacy; peers who use will influence other peers to use, and we know 
adolescents tend to leave treatment in groups of two or more (Dennis et al., 2005). 
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Research also shows the importance of positive social support as an integral adjunct to 
self-efficacy for achieving optimal outcomes after treatment (Prochaska & DiClemente, 
1986; Greenfield et al., 2000; Warren, Stein, & Grella, 2007).  
 This study will utilize a perspective from the life course research, initially 
developed for use in criminology. The life course perspective is a research lens that 
utilizes longitudinal data to identify significant markers and events that precipitate 
change. This perspective allows a hindsight perspective for studying human behavior, 
recognizing the importance of time, timing, and that sequential developments are 
consistently occurring during an individual’s lifetime (Lynch & Smith, 2005). The life 
course perspective has a long history in the health and public health fields, particularly in 
the social sciences (Lynch & Smith, 2005; Elder Jr, 1985; Elder, 1998).  
 When this approach was longitudinally applied to addiction, it was discovered 
that common features of successful remission among adolescents included for example, 
participation in formal treatment but with the additional presence of social capital (Evans, 
Huang, & Hser, 2011). Social capital are the positive resources that connect an individual 
to a productive, normative social environment. Social capital provides positive protective 
factors for an individual’s life, ultimately allowing for the building of esteem and 
resilience. For the nature of this study, social capital will be identified by the 
Environmental Support Index, which specifically looks at supportive environmental 
influences known to aid in transitioning from substance use to non-substance use.  
 Research findings within the populations of those with substance use disorders 
have generally shown that patterns of lifetime drug use and related problems are 
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extremely diverse (Hser et al., 2007). Severe or dependent users tend to persist in their 
drug use, and often, with repeated cycles of cessation and relapse occurring over 
substantial periods of their life span. It has long been argued that current treatment 
research views addiction as distinct acute cases or episodes, and that a “longitudinal, 
dynamic approach” (Hser et al., 1997) such as is found within the life course perspective 
would be more helpful.  
 Broadly, life course theory links individual biography to historical, geographical, 
and structural context in an effort to understand social change and individual 
development (Hser, Evans, Huang, & Messina, 2011). Adolescence is considered one of 
the most critical periods of change in the life course, with events literally altering 
developmental pathways during this time. A central tenet of life course theory, 
particularly in adolescent substance abuse, is that the timing of a transition sets its 
developmental impact (Elder, 1998). Life transitions (e.g., entry into first grade, divorce 
of parents) are always a part of social trajectories that give them a distinctive sense and 
shape; however, historical forces shape the social trajectories of family, education, and 
work, which in turn influence individual behavior and precise lines of development. By 
focusing on the trajectories across individuals’ lives, and the ways in which those patterns 
are shaped by the broader historical context and social structures, the life course 
perspective offers an extended framework that allows for identifying critical moments in 
the development of drug use trajectories, the events contributing to the persistence or 
change during the life span, and analytically ordering the events that occur during that 
course (Hser et al., 2007).  
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 The major thesis of life course theory—potentially relevant to the life course 
framework applied to drug use with adolescents—is that “social capital” and “turning 
points” are important concepts in understanding the processes of change (Sampson & 
Laub, 2005). The life course perspective also increases our understanding of the 
trajectories of drug-dependent adolescents who participate in social service systems, 
including addiction treatment, mental health services, criminal justice, child welfare, and 
primary pediatric services. Interactions with these social systems can trigger turning 
points for some adolescents, which suggest the potential for social services to identify, 
intervene, and introduce new possibilities to generate desirable change for substance-
abusing adolescents.  
 Research has shown that family structural conditions (e.g., poverty, large family 
size, and residential mobility) and family social processes (e.g., poor supervision, 
erratic/threatening discipline, and weak parental attachment) are strong predictors of 
adolescent delinquency (Sampson & Laub, 2003). It has also been argued that when a 
child's exposure is compounded with negative family conditions, life course persistent 
offending is most likely to occur (Moffitt, 1993). In this life course perspective, 
development is conceptualized as the constant interaction between individuals and their 
environment, coupled with purposeful human agency and what random molecular 
interactions. The recognition of developmental noise implies that "the organism is 
determined neither by its genes nor by its environment nor even by interaction between 
them, but bears a significant mark of random processes" (Lewontin, 2000). Thus, neither 
agency nor structural location can, by itself, explain the life course of crime (Sampson & 
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Laub, 2005) or addiction, and as further noted by Hser et al. (2007), a particular event 
does not universally lead to a turning point or a change in the same direction, and mere 
possession of higher levels of recovery capital will not necessarily result in cessation of 
substance dependence. However, the clear implications and correlations of both a 
treatment episode and social capital to the turning point of sustained sobriety indicate 
useful measures to explore.  
 In summary, it has been identified that long-term effects of treatment were 
mediated by the patient’s short-term response to treatment plus participation in aftercare 
and self-help (Scott et al., 2005). Similarly, it was found that the duration of involvement 
with services (including treatment, self-help, and periodic check-ins or monitoring) 
predicted recovery from drinking problems for a longer time frame (Moos, Schutte, 
Brennan, & Moos, 2004). Intensity of services may mediate the short-term effects of a 
specific service episode; conversely, long-term effects may be mediated by sustained 
engagement at any level. This is a noteworthy insight for health services as studies have 
shown increased success rates associated with a trajectory of treatments that provide an 
orderly progression of services, i.e., inpatient treatment, followed by residential 
treatment, then outpatient treatment, and participation in a self-help group (Evans, Li, & 
Hser, 2009).   
Problem Statement  
In sum, addiction, and substance use disorder is a pervasive and costly issue that 
is almost universally acquired and consolidated as a pattern of behavior during the 
adolescent developmental period. Furthermore, this disorder emerges from numerous 
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interacting factors that require developmentally informed, individualized treatment, to 
address the variability of needs present during adolescence. The unique and individually 
measured Common Liability to Addiction (CLA) isolates and identifies certain 
behavioral phenotypes, which if substance use is initiated, can fuse adolescent identity 
with this disorder. Numerous studies have confirmed this measure as indicating reliable, 
predictable, heritable risk for addiction, as well as verifying its accuracy and validity 
(Vanyukov et al., 2009; Hicks et al., 2012; Kirisci, Reynolds, Carver, & Tarter, 2013). 
There is reason to believe that the psychological trait of self-efficacy has some degree of 
influence over substance use disorder due to its connection to attained abstinence, and 
positive outcomes, thus the application of self-efficacy during adolescent treatment might 
moderate CLA influences.  
Although addiction is pervasive and recurrent during adolescence, treatment 
works, and high self-efficacy and further secure lengths of time in treatment also 
correlate with more positive outcomes (Garner, Godley, & Funk, 2008). Therefore, while 
one might expect the severity of CLA traits to influence patient choices and responses to 
treatment, there is a dearth of research regarding actual influences, as well as potential 
effects of self-efficacy or social resources on choices.  
 Adolescents in treatment programs often demonstrate high levels of resistance, 
little recognition of the disorder, and enter treatment under pressure from caregivers and 
loved ones. However, it is also known that resistance often represents peer influence 
(Chan, Dennis, & Funk, 2008; Dennis, White, & Ives, 2009), and the high opposition and 
rebelliousness that correlate with CLA (Hicks et al., 2012). Yet, treatment is still 
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effective during this period of development. Battjes, Gordon, O'Grady, Kinlock, & 
Carswell (2003) noted that coercive pressure was one of the primary influences on 
motivating adolescents; therefore, we might expect social capital to likewise moderate the 
relationship between CLA and continuing aftercare choices, a topic that has to date, not 
been studied. How would CLA levels present in an active adolescent population seeking 
treatment, and what role would self-efficacy and social capital have on influencing the 
predictive nature of these traits on continuing care choices? This knowledge is significant 
to treatment providers when establishing effective methods for enabling better treatment 
outcomes for the underserviced adolescent population.  
Purpose of the Study  
The purpose of the current study is to examine the effect of the continuous 
variable of the Common Liability to Addiction (CLA) in a treatment-seeking adolescent 
population. Specifically, this study seeks to explore how self-efficacy and social capital 
might interact in relation to the CLA phenotypes, to determine any correlation exists with 
treatment outcome decisions. The research questions below, along with the hypotheses 
underlying them, will be examined in this paper in an effort to determine the impact, if 
any, of these psychological, social, or genetic factors. Due to preliminary analysis 
indicating the relevance of family history of drug use being related to continuing care 
choices I also looked at family history of drug use. 
Research Questions  
 Research question 1: Is family history of drug use related to continuing care 
choices? 
  
28 
Research question 2: In a population of adolescents in treatment for addiction, is 
the Common Liability to Addiction related to continuing care choices?  
 Research question 3: Is refusal self-efficacy (RSE) related to adolescent 
decisions for continuing care choices?  
 Research question 4: Is social capital (SC) related to adolescent decisions for 
continuing care choices?  
 Research question 5: Are the independent variables related to outcome decisions 
of adolescents for continuing care choices?  
Do SE and SC interact? 
Do CLA and SC interact? 
Does CLA, and SE interact? 
 In the next two chapters, the relevant literature related to the current study and the 
methods for conducting the research are discussed. Chapter Two is a review of the 
literature related to the challenges and methodologies developed in defining perspectives 
for understanding addiction, and the resultant thoughts and implications for adolescent 
substance use treatment. In Chapter Three, the recruitment procedures, measures used, 
and proposed statistical procedures for examining the relationships among substance use, 
common liability to addiction, and use of treatment services in adolescents are outlined.  
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CHAPTER TWO: LITERATURE REVIEW 
 
Introduction  
 It is generally recognized that Adolescent Substance Use Disorder is one of 
society’s most pressing issues, and that resolving this disorder can be a difficult, long-
term process (McLellan et al., 2000). There is a large body of literature on the 
developmental and environmental risk factors that result in the 200% mortality rate 
increase in adolescence relative to childhood and adulthood (Johnston et al., 2011; 
Steinberg, 2012), as well as on the efficacy of addiction treatment (Dennis, 2014; Scott, 
2010; Winters et al., 2014).  
 However, adolescents face unique challenges that contribute to greater 
vulnerabilities than other populations (Belendiuk, 2014). With an elevated vulnerability 
to alcohol and drugs, they often experience higher levels of addiction, faster rates of 
onset, and develop addictions of greater severity, paradoxically not always evidencing the 
same physiological symptoms as adults (Winters et al., 2014). In addition, this period is 
also when co-occurring psychopathology most often appear, and compared to their non-
using peers, substance-using youth often possess additional disorders at greater rates 
(Kleinman, 1990).  
 While the field of addiction, overall, has made significant progress, especially in 
the last ten years, adolescent treatment gains have been a modest part of the challenge in 
treating adolescents in that they are characterized by a general heterogeneity in variables 
such as degree of substance use, motivation and impairment, as well as psychiatric co-
morbidities. However, due to practical considerations, most treatment is delivered in 
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group format (Knudsen, 2008) making specific tailoring to the particular needs of the 
adolescent subgroups more challenging. Consequently, commonly used group 
interventions may not address the needs of the youth enrolled in treatment, as they focus 
on acquiring outcomes for which the youth may have no intention nor desire to acquire 
(Dow, 2013).  
 The effectiveness of treatment has been established (Dennis, Ives, White, & 
Muck, 2008; Kaminer, 2011; Winters, 2012; Winters et al., 2014), and longer treatment 
durations, within a structured continuum of care, directly correlate with greater lengths of 
abstinence for both adolescents and adults (Dennis et al., 2007; Hser et al., 2001; 
Schuman-Olivier, 2014; Weiss, 2013). Yet, relative to adults, adolescents are in a 
continuous state of physical, social, cognitive, and psychological development, creating 
greater difficulty in regulating behavior, moods, and impulses (Rutherford, 2016). 
Compounding this is an evolutionary shift, developmentally timed to facilitate separation 
from the herd; changing their childhood focus to one of peer approval, pleasure pursuing, 
and risk-seeking (Albert et al., 2013; Spear, 2013). This produces intensity in 
adolescents, consuming them with the immediacy of the moment and negatively 
impacting their interest in addressing this disorder (Chan, 2011; Maisto et al., 2003; 
Kelly, 2003; Dennis et al., 2009; Godley et al., 2014).  
 However, the onset of substance use is occurring at younger ages, more youth are 
entering treatment with developmental deficits, and there exists a greater awareness of 
neurological disorders than previously noted (Chan, Dennis, & Funk, 2008). Since youth 
who use alcohol and drugs are more likely to face additional consequences such as 
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dropping out of school, experiencing unplanned pregnancies, or acts of violence, 
immediate intervention for substance use is a primary principle of treatment (Arbeit, 
2014). Youth do not have to be addicted to benefit from treatment, and quickly 
identifying substance using youth and engaging them in the appropriately integrated 
treatment is paramount to good outcomes (Gerstein, 1990).  
 While the literature remains clear on the effectiveness of longer-term treatment 
approaches (Brown et al., 1989; Cornelius et al., 2003; Meyers, 1995; Winters et al., 
2011) there is still a need to understand how to make quality treatment available across 
the continuum of care, and to extend these gains for longer periods of time (Winters et 
al., 2014). Post treatment relapse rates remain high for adolescents (Belendiuk, 2014), 
and even the reductions in substance-use seen after treatment, diminish over time 
(Tripodi, 2010; Waldron, 2008). To properly address this current trend, it is necessary to 
identify what types of treatment programs work best for whom, and what factors mediate 
and moderate engagement in this behavior change process (Winters et al., 2014).  
 This chapter reviews the literature related to treating substance use disorders, as 
well as those unique to adolescents. The first section will define addiction, and what 
standards insurance companies and medical professionals use for identifying and 
assessing treatment needs. Further discussed in this chapter are what is wrong with this 
approach; how this tactic means that each episode is treated in isolation to determine the 
appropriate level of placement, forcing treatment planning back to ground zero. 
 In contrast with this standard medical perspective, which depends on acute 
episodes of actual substance using, a genetic behavioral approach known as the Common 
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Liability to Addiction (CLA), developed to identify and even predict addiction will be 
explored in this chapter. This CLA approach can distinguish addiction as a separate 
construct outside the use of the substances themselves. This potentially means that the 
CLA construct might be useful in identifying significant client characteristics that might 
be receptive to particular methods, if recognized during treatment. An examination of 
client attributes and positive indicators currently thought to correlate with positive 
outcomes, and at what levels these factors have been associated with successful change 
are further discussed. Finally, the chapter ends with a description of the rationale and 
purpose of the current study.  
How is Addiction and Treatment Defined?  
 Before reviewing the literature, it is important to define addiction1. In a review of 
multiple terms, Smith (2013) used the US National Library of Medicine PubMed 
database (http://www.ncbi.nlm.nih.gov/sites/entrez) for terminology, classifications, and 
definitions developed and proposed by professional groups, national, regional, and 
international organizations and agencies, in an effort to produce consensus definitions for 
identifying misuse, abuse, and addiction to drugs. Standing on their efforts, this proposal 
will use the following American Society of Addiction Medicine definition. 
Addiction is a chronic, relapsing brain disease that is characterized by 
compulsive drug seeking and use, despite harmful consequences. 
 
 
To begin treating addiction it must first be identified, either by the person 
                                                        
1 While the literature is divided in its use of terms, with some researchers using addiction while 
others using Substance-Use Disorder (SUD); this proposal will use the term addiction as 
synonymous with substance-use disorder. 
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suffering from the disorder or through a brief screening process from a medical 
professional. Once identified, the scope and severity can be assessed, and an integrated 
treatment plan and referral process begun. Initially, screening is the beginning of 
treatment and usually occurs in primary care clinics, school counseling or nurse’s offices, 
community crisis centers, or emergency departments. Treatment and assessment have an 
ongoing iterative relationship throughout the process as clinicians and clients continue to 
work together to alleviate the clients’ most pressing concerns (Flynn, 2008).  
 While a client is in a detoxification, or medically monitored stabilization program 
for the initial cessation from substances, the purpose is to help the client prepare for 
additional treatment (CSAT & Treatment, 2006). Detoxification is by itself not 
considered treatment. Successful detoxification is when the client continues in a 
continuum of care with some other form of addiction treatment (Kertesz, 2003). 
However, as the client’s originally discomforting symptoms begin to ease, and the initial 
physical pain and illness of withdrawal subsides, the psychological symptoms of 
withdrawal intensify. Clients may not even recognize they are craving as their anxiety 
increases, anger and emotions become unpredictable, and depression arises in the absence 
of the substances they are used to (Koob & Volkow, 2010). This includes a shift away 
from positive reinforcement to negatively reinforced drives and automaticity in behavior, 
as the patients react to prominent drives now overwhelmed by anxiety, dysphoria, and 
other aberrant neuroadaptations (Koob & Volkow, 2004). This produces the impulsive, 
compulsive, self-destructive behaviors that lead to relapse and are the hallmark of 
addiction (Koob & Volkow, 2010).  
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 Every client presents uniquely, and each new affective or behavioral change must 
be assessed and treated for optimal outcomes (CSAT C. f., 2005). Nevertheless, duration 
of continuous treatment remains one of the most reliable indicators of successful change 
(Dennis et al., 2007); the American Society of Addiction Medicine (ASAM; Ries, 2014), 
the American Psychiatric Association (APA; Galanter, 2014), and the National Institute 
for Drug Abuse (NIDA; NIH, 2014) all suggest that treatment episodes of less than 90 
days are destined to be ineffective.  
The Medical Model of Addiction  
 The American Society of Addiction Medicine (ASAM) has developed a set of 
criteria, formerly known as the Patient Placement Criteria (PPC; Mee-Lee, 1996) that is 
used for adolescents and adults to provide individualized and comprehensive treatment 
plans. These treatment plans have been designed using validated placement criteria to 
match clients to the most appropriate interventions and levels of treatment. Using a 
multidimensional assessment approach over five broad levels of treatment, the criteria are 
based on the degree of direct medical management needed, as well as the structure, 
safety, security, and intensity of treatment services indicated for optimal outcomes 
(American Society of Addiction Medicine [ASAM], 2011; Mee-Lee & Shulman, 2015).  
 The ASAM criteria are continuously monitored by a steering committee and are 
updated based on two factors: 1) empirical data that indicate opportunity for improved 
predictive validity rather than by anecdotal input or face validity, and 2) treatment system 
changes. Similar to the process that the American Psychiatric Association follows to 
revise the Diagnostic and Statistical Manual of Mental Disorders (DSM), any changes are 
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made based on research data (American Society of Addiction Medicine, 2011; Mee-Lee 
& Shulman, 2015).  
 The ASAM criteria is currently used in 30 states, and when utilized by doctors, 
treatment centers, addiction professionals, and insurance providers, it guides addiction 
treatment by identifying different problem areas and determining the best treatment fit for 
optimal outcomes. This assessment-style approach is designed to individualize treatment, 
while controlling for cost (Inaba, 2007). Such customized placement for individuals 
looking to make changes to their substance use behaviors requires evidence-based care, 
accurate assessment by trained professionals, and that referring doctors stay abreast of the 
current state of treatment, know findings from current treatment research, and be aware 
of local treatment availability.  
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Figure 1 The ASAM Criteria 
 The ASAM factors consider six dimensions (Figure 1) beginning with symptoms 
of intoxication or withdrawal. Next, sequentially, are the severity of biomedical 
conditions due to the substance use; the emotional, behavioral, and cognitive 
complications; patient motivation-usually termed readiness to change; relapse history, 
environmental/cultural conditions of the patient; and last but not least, potential for 
recidivism within the expected recovery environment (Mee-Lee & Shulman, 2015). 
However, while the ASAM criteria provides an evidence-based research driven model for 
a continuum of care, the first dimension’s dependence on current intoxication or 
withdrawal belies the process of treating addiction as a chronic medical condition akin to 
diabetes or asthma (McLellan et al., 2000). Instead, meeting level of care requirements 
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for detoxification requires each episode of treatment, and more importantly coverage by 
insurance, to begin at the acute care level with the recent use of substances.  
 In similar fashion, the current Diagnostic and Statistical Manual version 5 (DSM-
V) is the current guide for behavioral health counselors and practitioners (American 
Psychiatric Association, 2013). The DSM-V was intended to improve the current 
perspectives contained within the DSM-IV-TR (American Psychiatric Association, 
2000), and yet rather than “addiction” it describes the phenomenon of substance-use 
disorder (SUD). This disorder is described as a potentially progressive cluster of 
cognitive, behavioral, and physiological symptoms that can be catalogued and grouped 
by the clinician, determining the severity of the disorder on a continuum. The disorder is 
then classified as mild, moderate, or severe, based on the presence of particular criteria. 
While attaining diagnostic utility through identifying substance-induced biological 
conditions and certain behaviors, and each symptom and criterion must be catalogued and 
individually categorized for every substance used in a 12-month period. 
 For each client with a substance-use disorder, clinician’s must record the code for 
the class of substance e.g. Opiate, plus the specific substance e.g. Percocet. Thus, the 
establishment of a substance-use disorder is qualified by first establishing a problematic 
pattern of use leading to clinically significant impairment or distress, as manifested by at 
least two of the following symptoms occurring in a 12-month period. The number of 
criteria met establishes the severity of the disorder with 2–3 being mild, 4–5 equaling 
moderate, and 6 or more establishing a severe substance-use disorder. Therefore, if a 
client with an Opiate disorder using Percocet reported the following: continued use 
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despite significant-substance related problems, taking larger amounts than intended, a 
failure to fulfill obligations, recreational activities avoided, tolerance-the need to use 
more to achieve the desired effect, and withdrawal, they would qualify for a severe 
Opioid-Use Disorder (American Psychiatric Association, 2013 ).  
Problems with this Perspective  
 Unfortunately, the consequence of describing the problem of addiction in the way 
that the American Society of Addiction Medicine does in their DSM, with regards to 
patient placement guidelines or when diagnosing the presence or severity of addiction, is 
that it places the focus of addiction treatment, directly on the sum of the effects of the 
substances used, rather than the underlying pathology (Vanyukov et al., 2012). This is not 
unlike suggesting that the problems for an individual who repeatedly drinks pesticides are 
the toxic effects on the stomach, throat, and mouth, while avoiding the obvious suicidal 
ideation and psychological issues that would perpetuate the continuing decision to 
swallow poison.  
 In essence, each episode for Addiction is treated in isolation, to determine the 
level of current intoxication, symptoms of tolerance and withdrawal, to determine levels 
for treatment funding, level of placement, and the appropriate interventions required. 
While some have argued instead that addiction is a chronic, relapsing disease similar to 
asthma or diabetes, and necessitate a disease model approach (Koob & Volkow, 2010; 
McLellan et al., 2000), the current medical approach forces treatment planning back to 
ground zero with each relapse. This methodology has deadly consequences when applied 
to the oft relapsing population of developing, impulsive, and thrill-seeking adolescents.  
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Adolescent Complications  
 The diagnosis of adolescents is likely to be more complicated as they tend to be 
poly-drug users, and also tend not to demonstrate the same symptoms as adults. This 
diagnostic methodology limits predictive utility and presents challenges for youth, not 
only because they may not always demonstrate the same physiological consequences 
adults might (Winters et al., 2014), but also because establishing addictive patterns in a 
developing brain often requires much more time to remove (Dennis, 2014). According to 
the National Institute for Drug Abuse (NIDA, 2014) the adaptations evidenced in the 
brain that result from chronic drug exposure are long-lasting, and addiction must properly 
be viewed as a chronic disease (Volkow, 2004). From this perspective, as with other high 
relapse-rate chronic diseases such as asthma, diabetes, and hypertension, long-term 
durations of treatment, up to many years and even decades, may be required, (McLellan 
et al., 2000).  
 However, during the period of adolescent development, self-regulation acquisition 
lags curiosity, which delays adolescent abilities to comprehend natural consequences 
(Luciana, 2012). Youth often will not experience or display traditional withdrawal 
symptoms (Winters et al., 2014), making formal treatment seem unnecessary and often 
not meeting qualification guidelines for reimbursement (Sterling, 2010). Concurrently, 
adolescent drives produce erratic emotions and impulses that combine with cravings 
(Casey & Jones, 2010) that compete; the belief that they need to either address addiction 
or be more concerned with other risk-taking consequences (Albert, 2013; Steinberg, 
2010).  
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 Substance using youth show higher levels of neuropsychological dysfunction and 
deficits (Ehrenreich, 1999; Nagel, 2005; Pope, 2003; Tarter, 2004), and with the natural 
vigor and resilience of adolescence, they do not experience the same physical tolls and 
health consequences as adult substance users (Maisto et al., 2003). This combined lack of 
reality-based interoception (Koob & Volkow, 2010), poor decision-making (Geier & 
Luna, 2009), and impulsivity (Schneider, 2012) is not only a common attribute in 
adolescence, it creates the perfect storm for the development and perpetuation of 
addiction and relapse (Wills et al., 2011). In addition, affecting this lack of insight is the 
inability to foresee the burden of substance induced health concerns until older (Maisto et 
al., 2003). Unfortunately, the continued neurological assault of drug-use only perpetuates 
the impairments (Gulley, 2013; Pokhrel et al., 2013; Yücel, 2007) as adolescents pursue 
pleasure, risk-taking, and peer approval (Albert et al., 2013).  
Final Authority for Treatment Decisions  
 The Code of U.S. Federal Regulations, Title 42 part 2 (2002) concerns the 
confidentiality of patient records. This was originally designed to protect privacy, to 
allow the freedom to enter drug and alcohol abuse treatment without fear of stigma 
(Geppert, 2009). However, 42 CFR can impose restrictions on parents and caregivers as it 
places the final authority for choices about substance use treatment on the adolescent 
patient currently receiving treatment. This means that minors in treatment are empowered 
with the same legal anonymity as adults when it comes to treating their condition. Thus, 
the final decision about curtailing substance use disorder is left in the hands of the people 
least developmentally qualified to do so: the adolescents themselves. This often leads to 
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them choosing extremely vulnerable recovery environments (Dawes, 2000), making it no 
surprise that nine out of 10 adults with addiction report starting in adolescence (CASA, 
2011).  
 Since adolescents are in a developmentally shifting period of growth (Casey & 
Jones, 2010 2010) many of the ASAM dimensions (Figure 1) can be difficult to identify, 
and the critical aspect of willingness to stop using often remains unacknowledged by the 
youth (Maisto et al., 2003). As the resilience and physical vitality present during the 
teenage years, coupled with the limited amount of exposure may cause youth to not 
display the same physical effects from using substances, showing very little to none of 
the tolerance and withdrawal symptoms required for diagnosis (Winters, 2014). This can 
make standard treatment perspectives insufficient and prolong recovery for youth during 
a highly vulnerable and crucial intervention period. This is just one more reason why it is 
critical that research isolates and identifies new factors and attributes that might assist 
adolescents in addiction treatment.  
Summary of Problems in Adolescent Addiction  
 As imaging provides new insights on how the human body and brain interacts 
with the environment, medical perspectives of addiction and treatment continue to 
evolve. Researchers and providers have made great efforts to update treatment with the 
scientific findings to create more efficacious “evidence-based practices.” However, the 
current diagnostic definitions used to understand and treat addiction may be insufficient 
when it comes to treating adolescents as long as the criteria remain primarily focused on 
the substances and the physiological consequences, rather than the phenomenon of 
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addiction itself.  
 By definition, addiction is the compulsive use of substances marked by impaired 
control, cravings, and neurobiological dysfunction that occurs despite personal harm or 
negative consequences to the user; and severe cases are seen as a chronic, relapsing 
disease akin to asthma and diabetes. The Diagnostic Statistical Manual identifies 
addiction as substance use disorder, and as a grouping of symptoms that all involve 
initially taking a substance. This is described as a potentially progressive cluster of 
cognitive, behavioral, and physiological symptoms that can be catalogued and grouped 
by a clinician, determining the severity of the disorder on a continuum. The disorder is 
then classified as mild, moderate, or severe, based on the presence of particular 
conditions. While attaining diagnostic usefulness through identifying substance-induced 
organic conditions and certain behaviors, each symptom must be individually categorized 
for every substance used in a 12-month period. 
 For each client with addiction, clinician’s must record the code for the class of 
substance e.g. Opiate, plus the specific substance e.g. heroin. Thus, the formulation of a 
substance-use disorder is qualified by first establishing a problematic pattern of substance 
use leading to significant impairment, as manifested by at least two of the following 
symptoms occurring in a 12-month period. The number of conditions met establishes the 
severity of the disorder with 2–3 being mild, 4–5 equaling moderate, and 6 or more 
establishing a severe substance-use disorder. Therefore, if a client with an Opiate disorder 
using heroin reported the following: continued use despite significant-substance related 
problems, taking larger amounts than intended, a failure to fulfill obligations, recreational 
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activities avoided, tolerance-the need to use more to achieve the desired effect, and 
withdrawal, they would qualify for a severe Opioid-Use Disorder (American Psychiatric 
Association, 2013).  
This is problematic as focusing on the substance first perpetuates a simplistic 
understanding of the problem, and the answer is to simply alleviate the acute 
physiological concerns without necessarily addressing the underlying issues. Treating 
adolescents with addiction is already challenging enough. The complexities of the 
developing brain make adolescents especially vulnerable to addiction. With the rapid, 
erratic nature of social identity and brain development occurring alongside the upsurge in 
peer affiliation, impulsivity, and a pleasure-driven focus only on the immediacy of the 
moment, the utility of traditional treatment with youth is already limited. Enforcing the 
physiological standards of intoxication, tolerance, and withdrawal pose additional 
problems with youth, and forcing treatment into chunks of acute episodes gravely affects 
the ways in which we approach this problem.  
The Common Liability to Addiction  
 People in the field have long wondered and develop ideas on the etiology of 
addiction. Studies have looked at the Gateway Hypothesis (Vanyukov et al., 2012), and 
differing trauma events as being associated with the development of substance use 
disorder (Norman, Tate, Anderson, and Brown, 2007). This section describes an alternate 
perspective than the DSM within which to view addiction. The Common Liability to 
Addiction method is just one other theory but one based on a genetic behavioral 
perspective. Though unconventional it is possibly more informative way of identifying 
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addiction that does not depend on looking at substance use, or specific physiological 
indicators such as tolerance or withdrawal. This approach instead relies on behavioral 
characteristics that describe The Common Liability to Addiction (CLA). In this section, 
the development of the CLA and how the field of genetics has contributed to a more 
nuanced conceptualization of addiction, separate from classifying the substances 
themselves, which may be particularly helpful in addressing adolescent addiction is 
described. Further discussed is how research and utilization of twin studies and family 
cohorts, along with longitudinal data has demonstrated a reliable and predictive ability 
that can potentially be used to more accurately assess continuing care needs of different 
populations.  
 In contrast with most current conceptual depictions of addiction, which address 
only the drug use in order of initiation, the concept of a Common (general) Liability to 
Addiction (CLA) involves the mechanisms and bio-behavioral characteristics that apply 
to the entire development course of the disorder, as well as changes in the risk (Vanyukov 
et al., 2012). Whereas dependence is accepted in the current classification (e.g., DSM, 
ASAM ) as based on physiological drug response, addiction, defined as compulsive drug-
seeking and use despite adverse consequences, may be more relevant as a description of 
the complete clinically significant phenotype. Dependence is a normal biological 
adaptation to drug action, occurring separate from drug abuse as in pain treatment. 
However, it is addiction, with its injurious behaviors, that results in health and other 
resultant problems (Vanyukov et al., 2012). 
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Development of the CLA  
 The aforementioned CLA indicates a behavioral/psychological trait, manifesting 
in a range of behaviors grounded in the mechanisms of socialization and 
affective/cognitive regulation that has deep evolutionary roots (Vanyukov et al., 2012). 
Addiction and other disorders are highly comorbid, often existing alongside numerous 
possible disorders, as evidenced in large national and international epidemiological 
surveys (Degenhardt & Hall, 2001; Johnston et al., 2011; Administration, 2013) with 
higher than expected rates (Palmer et al., 2012). It has long been known that alcoholism 
and addiction commonly run in families (Kirisci et al., 2012), and as such, the specific 
need for an assessment of the risk for addiction has become apparent (Conway et al., 
2010). This led the Center for Education and Drug Abuse Research (CEDAR) to develop 
the Common Liability to Addiction (CLA) to quantify any individual’s overall 
transmissible addiction risk for addiction on a normally distributed scale (Kirisci et al., 
2009; Vanyukov et al., 2009).  
 In genetic research, the risk for any disorder can be conceptualized as a 
manifestation (phenotype) of a continuous unobservable trait known as its liability 
(Falconer, 1965). The term “liability” was introduced to human genetics by Falconer to 
describe traits that are not inherited in the same way as single-gene or monogenic traits, 
but nonetheless demonstrate predictable familial distribution. Among multiple 
generations it is noted that there often exists not only the tendency to develop a disease, 
but also the full arrangement of the peripheral conditions that make an individual 
predisposed to developing that disease. However, as Falconer theorized, overcoming the 
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all-or-none difficulty of predicting disease inheritance requires the establishment of the 
underlying sequence of attributes immediately related to the disease. Measuring the grade 
of these attributes provides the ruler for the degree of affectedness or of normality, with 
all individuals above a certain value exhibiting the disease, while all those below it not 
doing so (Falconer, 1965; Vanyukov et al., 2003b)  
 Phenotyping is a major advancement for research into addictions, as it identifies 
characteristics associated with this underlying sequence associated with addiction 
(Vanyukov et al., 2012). This process has allowed research methods to switch from using 
diagnostic comparisons of “addicted” versus “non-addicted” to a more holistic 
conceptualization, using measures taken from observable facets of substance use with 
these underlying variables to represent a continuously-distributed quantitative measure of 
a person’s liability to addiction (Agrawal et al., 2012). The continuous measures are the 
factors known to be heritable, and this heritability overlaps significantly with genetic 
influences on addiction (Dick et al., 2011; Grant et al., 2009; Kendler et al., 2011; 
Agrawal et al., 2012).  
Variation in liability as an unobservable trait is contributed to and influenced by 
any number of things, e.g., genetic and environmental factors, physiological processes—
biochemical or neurochemical—as well as temperamental or personality characteristics 
and beyond. These observed displays can be isolated and used to measure the range of 
liability (Vanyukov et al., 2003a). When the observable characteristics of a disease, or its 
phenotypic values, surpass a certain point on the unobservable (latent) scale of liability 
(Vanyukov et al., 2000), a threshold is surpassed and the afflicted person exceeds the 
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tipping point, develops the disease, and the visibility of that disease can then be 
diagnosed.  
 Utilizing longitudinal designs and study cohorts with half of participant families 
having a father with a drug use disorder, CEDAR catalogued specific risk factors shared 
between parents and sons. The result, after years of development, was the Common 
Liability to Addiction index (CLA), which use various validated psychometrics and 
measurements known to identify personality types, temperament, attitudes and beliefs, 
correlating with substance use (Vanyukov et al., 2003a). Then utilizing these large sets, 
originally selected for potentially identifying and measuring variables related to addiction 
risk and propensity, and statistical methodologies such as factor analysis and IRT, select 
items were transformed into a unidimensional construct (Conway et al., 2010). Using 
self-reports from sons of affected fathers between the ages of 10 and 12, then 
triangulating the data with information from mothers and teachers, the scores calculated 
produce a child’s unique transmissible liability index, which identifies the presence of a 
Common Liability for Addiction, or the percentage of heritable risk the child has for 
developing addiction (Vanyukov et al., 2012).  
Predictive Validity of the CLA  
 The presence of this common liability to addiction (CLA) has been accurate in 
predicting addiction up to 12 years later in numerous samples (Kirisci et al., 2009; Kirisci 
et al., 2005; Vanyukov et al., 2009). To further elucidate the properties of transmission 
liability risk assessment, as well as its ethnic variations, a cohort of 10- to 12-year-old 
sons of substance-using fathers and non-substance-using fathers were followed 
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longitudinally. Vanyukov et al. (2009) examined the CLA and demonstrated its statistical 
validity for accurately identifying high heritable risk for developing addiction in males, 
using the continuous scale of observable characteristics that comprise the liability. 
Findings show that this common transmission liability index is a valid and reliable scale, 
highly predictive, e.g., O.R. = 1.81, 95% with a confidence interval of 1.12–2.30 for 
substance use disorder (Kirisci et al., 2009; Vanyukov et al., 2009). The scores in the 
CEDAR cohort at ages 10–12 were more accurate in predicting an individual’s addiction 
by early adulthood than when examining parental drug use alone (Vanyukov et al., 2009). 
This liability to be highly heritable (H2 = 0.79) is futher demonstrated in twin studies 
(Hicks et al., 2012; Vanyukov et al., 2009). 
Another study focused on identical and fraternal twins who were consecutively 
examined to analyze the transmission liability index’s characteristic variance. The twin 
study demonstrated that the common liability characteristics have a high genetic basis, 
with a greater correlation in identical versus fraternal twins. This study found that while 
being in the high-risk group (sons of substance-abusing fathers) was a good predictor of 
addiction, utilizing the CLA allowed for evaluation of risk on a continuous scale without 
needing access to parental data (Kirisci et al., 2009).  
Phenotypes and Liability  
 The liability index created by CEDAR, providing a continuous measure of 
liability—namely for the CLA—makes known the accumulated sum of behavioral 
characteristics (phenotypes) that underlie addiction risk correlated among generations 
(Kirisci et al., 2013). The question of whether a trait (such as a liability to addiction) or 
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its phenotype (visible characteristics such as addiction) is contributed to more by genes or 
environment would be equivalent to asking whether water is made up more of oxygen or 
hydrogen (Vanyukov et al., 2003a). All affected individuals will have both a certain 
degree of genetic predisposition and a certain amount of environmental risk (Vanyukov et 
al., 2000). Naturally different disorders will have unique phenotypes indicating liability. 
Diseases such as cancer or diabetes provide distinct indicators such as cell growth or the 
presence of abnormal physical characteristics. For liabilities to behavioral disorders such 
as addiction, there is no definitive consensus between normal versus pathological, and the 
thresholds are identified using the Diagnostic and Statistical Manual of Mental Disorders 
V (American Psychiatric Association, 2013). However, a major limitation of this 
approach is that it currently requires the individual to already have initiated the negative 
behavior. To diagnose someone with substance use disorder requires the use of 
substances, while the CLA can identify the risk before a child is exposed to substance 
use.  
 The traits that make up the CLA are surprisingly varied. While addictive disorders 
have long been associated with antisocial behavior and disinhibited personality traits such 
as impulsivity, sensation-seeking, rebelliousness, and aggression (Krueger, 1999; 
Krueger et al., 2002; Krueger & Markon, 2006), the spectrum of characteristics employed 
in the CLA is broader than in the scales measuring such externalizing traits (Kirisci et al., 
2012). Whereas addiction risk is phenotypically and genetically correlated with 
disinhibition and externalizing behaviors in childhood (Elkins, McGue, & Iacono, 2007; 
Grove et al., 1990; Krueger et al., 2002; Iacono, Malone, & McGue, 2008), many 
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additional psychological characteristics are also related to risk for addiction (Bechara, 
2005; Elkins, King, McGue, & Iacono, 2006; Giancola, Martin, Tarter, Pelham, & Moss, 
1996; Spear, 2000). Of these, disinhibition is only a subset of the indicators for the 
continuous latent trait representing the component of addiction liability transmissible 
across generations (Vanyukov et al., 2003a; Vanyukov et al., 2003b; Vanyukov et al., 
2009). As addiction is also known to be influenced by many well-researched and 
common environmental factors, most notably peer groups and poverty (Sloboda Glantz, 
& Tarter, 2012), the fact that no shared environment component has been identified for 
the common liability to addiction index reveals the salience of genetic effects (Vanyukov 
et al., 2009).  
Minnesota Twin Family Study (MTFS)  
 This study will utilize the common liability to addiction indexing methods of the 
Hicks et al.’s (2012) study. Utilizing questions to isolate particular phenotypes within the 
Minnesota Twin Family Study (MTFS), Hicks et al. (2012) designed a CLA index similar 
to the ones used by CEDAR to isolate common liabilities within an extant data set. This 
study’s findings verified the use of CEDAR’s CLA, establishing further predictive 
validity for the Common Liability to Addiction, and added to the research on the genetic 
basis of the disinhibited and oppositional behavior often associated with the addictive 
personality (Iacono et al., 2006).  
 In the Minnesota Twin Family Study, 11-year-old twins participated in a family-
wide, multi-method assessment covering several childhood disorders including attention 
deficit disorder (ADD), attention deficit hyperactive disorder (ADHD), conduct disorder 
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(CD), oppositional defiant disorder (ODD), and major depressive disorder (MDD). Both 
mothers and twins reported on symptoms in a longitudinal study of 2,510 sets of twins 
and their families. At age 17, twins participated in a second follow-up assessment. During 
this assessment, nicotine, alcohol, and illicit drug use was identified. Using the same or 
similar items and methods to calculate the transmission liability index, Hicks et al. (2012) 
was able to estimate the heritability of CLA scores, and to determine how well CLA 
scores predicted addiction. CLA scores calculated at age 11 were correlated with 
outcome measures of overall substance use and abuse and behavioral disinhibition 
collected at the age 17 assessment. 
It was found for the MFTS sample that CLA scores at age 11 greatly correlated 
with substance abuse outcomes in adolescence. Using biometric analysis of the data, 
Hicks et al. (2012) was also able to parse out the influence of genetic effects, as well as 
any shared and non-shared environmental influences. They found that the CLA scores 
were uniformly high within the identical twin sets versus a relatively low correlation 
within the fraternal twin sets, thus identifying a large genetic effect (Hicks et al., 2012). 
They also determined that there were no significant differences based on gender, 
implicating that the liability index had a high heritability for both males and females.  
 Despite using a different sampling strategy and slightly different assessment 
questions, modeling CEDARS CLA with the Minnesota Twin Family Study exhibited the 
index’s predictive potential for accurately identifying adolescent substance abuse prior to 
onset. The study demonstrated the benefit of extending the research with extant data sets, 
allowing for further explication of etiology with additional risk factors while providing an 
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opportunity to examine outcomes and potential influences to assist preventive and/or 
interventional efforts. Though both CEDAR and the Minnesota Twin Family Study had 
the benefit of triangulating corroborating information from mothers and teachers, 
Vanyukov et al. (2009) argue that as a population target group passes the age of risk, 
addiction diagnostic/severity information collected directly from group members can be 
used. This allows the use and validity of self-report in identifying common liability traits.  
 A key finding regarding substance use is that while there are substance-specific 
risk factors, much of the vulnerability underlying addiction is the same across different 
drugs such as alcohol, nicotine, or illicit drugs, especially for the early onset of substance 
use that emerges in adolescence (Iacono et al., 2008). This commonality suggests the 
concept of a freestanding addictive tendency outside of the actual drug use. An innate 
disposition always requires an environmental impetus to activate potential. For substance 
use disorder, the initiation of substance use becomes the match that lights the kindling, 
tipping a predisposition beyond the threshold and igniting the forest fire that addiction 
becomes.  
 Kirisci et al. (2013) demonstrated this threshold effect in a longitudinal study of 
412 boys who were tracked from the ages of 10 to 22, to determine the common liability 
to addiction index’s ability to determine who had the potential to develop marijuana 
addiction. A recent challenge for addiction specialists who work with youth, marijuana is 
the most-abused illicit drug in the world, and marijuana lobbyist groups’ successful 
efforts have allowed for decriminalization and even legalization in some states. Kirisci et 
al.’s (2013) study looked at 22-year-old men who have been prospectively tracked since 
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they were 10- to 12-year-old boys. The boys were assigned to one of three groups when 
they attained 22 years of age: (1) lifetime diagnosis of CUD (N = 64); (2) cannabis use 
without qualifying for CUD diagnosis (N = 178); and (3) no lifetime history of cannabis 
use (N = 170).  This study identified the validity of the CLA with addiction outcomes for 
marijuana in young adults, revealing that the first exposure to and use of marijuana 
became a turning point only for some of the children, setting them off onto a new 
developmental pathway, with the progression of liability behaviors and characteristics 
growing more and more severe over time. However, only those who scored the highest on 
the CLA suffered this fate. By the age of 22, some (n=170) had never smoked marijuana, 
some (n=68) who smoked marijuana became addicted, and others (n=178) who smoked 
marijuana did not become addicted. This 12–year study revealed that of the boys who 
smoked marijuana, only those with a high severity of CLA scores prior to doing so 
developed addiction (Kirisci et al., 2013). Further, it was demonstrated that the first 
exposure to cannabis was foreshadowed by higher CLA scores, and that those scores 
increased over time only for the boys who developed addiction. The other cohort who 
smoked but did not develop addiction, showed no changes in CLA, whereas a linear 
decrease in severity of CLA scores was displayed for the group that never tried the drug. 
It appeared that only for the youth with the higher transmissible risk was marijuana a 
“gateway” drug.  
Validity of Reducing CLA Questionnaires  
 Additional work has focused on reducing the number of questions needed to 
accurately identify the common liability to addiction. Kirisci et al. (2012) used the 
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process of computer adaptive testing (CAT) to attempt to maintain the validity of CLA 
with two different samples, one comprising 318 males and 107 females and attained from 
a CEDAR family sample cohort who were evaluated two years later to determine 
transition to cannabis use disorder. The other including 276 twin pairs from The 
Twinsburg Festival in Twinsburg, Ohio. 
The original CEDAR CLA used 48 questions to correctly forecast the 
transmission liability for addiction; however, using CAT (Kirisci et al., 2012; Kirisci et 
al., 2013) the number of questions was reduced by over 70%. The researchers have 
suggested that this would be beneficial in allowing for shorter screening times and greater 
access, perhaps even becoming available to pediatricians for identifying liability in 
regular developmental screening settings. Unfortunately, the common liability to 
addiction traits most correlated with developing addiction represented a severe behavioral 
dysregulation and a high propensity for social deviance (Kirisci et al., 2013). These anti-
social clients are often the most difficult to reach with prevention and treatment efforts 
alike (Stein et al., 2013).  
Summary of Common Liability to Addiction  
 The genetic-behavioral findings within the addiction treatment field have 
independently identified that neurological aberrations such as anxiety, ADHD, conduct 
disorder, and/or oppositional defiant disorder, often co-occurring with addiction, most 
always precede the actual initiation of substance use (Vanyukov et al., 2003a; Conway et 
al., 2010). Since addiction, like many other genetic potentialities, require environmental 
stimulus to be galvanized (Kirillova et al., 2008), the use of any mood-altering substance 
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illegally acquired or legally prescribed by a doctor, would still have the potential for 
manifesting addiction in an individual.  
 This dissertation is interested in the biological and heritable contribution to 
addiction, and this section provides research evidence that addiction is part of a genetic 
heritable trait, rather than something acquired via a gateway process. Through the use of 
phenotyping, researching, and assessment, the Common Liability to Addiction (CLA) 
concept has shown not only to be reliable, but also predictive in identifying future 
addiction. It is also understood that while individual classes of drugs may have unique 
risk factors, many of the underlying liability characteristics are the same across the 
spectrum of substances. This suggests a free-standing vulnerability or addictive tendency 
outside of substance use. This holds tremendous promise for prevention work, both for 
prevention of substance use initiation, and early intervention and the halting of escalation 
and recidivism. Unfortunately, one of the most common trait characteristics of the CLA 
is a rebellious and anti-social proclivity that often challenges the opportunities offered by 
treatment.  
 The CLA also evidences that addiction is not dependent on any presumed severity 
of the initial drug used. This concept, which led to the myth of the “gateway drug” 
assumption, has perpetuated beliefs that some psychoactive drugs are safer than others. 
Currently, this belief is why clients might actually switch addictions from one substance 
to another, or even from substance addiction to new behavioral manifestations such as 
gambling, sex, or overeating (Volkow et al., 2013). Whether it is marijuana that leads to 
heroin addiction or heroin use that leads to alcoholism, likewise relapsing to addiction, is 
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not solely reliant on avoidance of any particular class of drugs once addiction has already 
been activated and established.  
 Even so, the continuous development and exploration of the common liability to 
addiction demonstrates much about the heritable nature of addiction, and the potential of 
using this approach can guide identification and treatment approaches. One direction for 
further exploration is research that focuses on adolescent populations in treatment. For 
example, to the best of my knowledge, the CLA has never been studied in a population of 
adolescents actively attending addiction treatment. Identifying the range of common 
liability to addiction variance in such a population, as well as examining the moderating 
effect of traditional outcome indicators such as positive psychological traits, and 
protective environmental factors, may assist clinicians and treatment programs in 
achieving optimal outcomes for adolescent clients.  
The Role of Self-Efficacy in Resolving Addiction  
 Multiple research studies have identified many factors that predict treatment 
response, substance use outcomes, and relapse (Anderson, 2006; Ramo, 2008; Chung, 
2006; Kelly, 2010; Thush, 2008; Wei, 2011). Some important predictors have included 
prior treatment experiences, criminal justice system involvement, and psychiatric 
comorbidity, while subjective factors have included motivation for abstinence, self-
efficacy, and coping skills (Dennis, 2005; Godley, Godley, Dennis, Funk, & Passetti, 
2007; Kelly, 2010; Sussman, 2008). In this section, the research on the psychological 
factors that have been most heavily identified in successful outcomes for addictions, the 
construct known as self-efficacy, will be discussed through examining some of the 
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different ways in which it has been measured, and the research of its efficacy with 
different populations. Some of the unique challenges in interpreting this construct, 
particularly when interpreting the construct in connection with addiction and with 
adolescents will also be discussed. 
 Bandura (1977) conceptualized efficacy as the belief that one can perform a 
certain behavior to produce a desired outcome. Self-efficacy is defined as a person’s 
belief about their own ability to achieve various levels of performance in order to produce 
a desired effect (Bandura, 1977). The degree of such belief is influential in determining 
how people feel, think, and motivate themselves, as well as how they behave (Bandura, 
1994). The level of self-efficacy also determines the amount of effort a person will 
ultimately put into the process of trying to change (Bandura, 1977; Bandura, 1982; 
Bandura, 1986; Bandura, 1999), and how persistent an individual will be if he or she is 
not initially successful (Chavarria, 2012).  
 Bandura and Locke (2003) reviewed nine meta-analyses that examined self-
efficacy beliefs across different areas of human performance, e.g., occupational, 
academic, psychosocial, and health behaviors, and concluded that self-efficacy was a 
strong predictor of coping, performance ability, and determination during difficulty. 
According to Bandura (1999), perceived self-efficacy is the foundation of human agency: 
unless a person believes they can change, they will have little desire to act.  
 Further, Bandura (1986) showed that self-efficacy can influence actions 
independently of past behavior, and that perceived self-efficacy predicted future behavior 
better than past performance. This is of particular interest in the application of self-
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efficacy theory to substance abuse research. If self-efficacy is shown to be helpful to the 
success of patients with substance use disorders, this can counteract a history of negative 
past performance marred by substance use.  
 Self-efficacy has been identified as a necessary component of change (Nigg & 
Courneya, 1998), and the construct has been consistently applied to the study and 
treatment of addictive behaviors, with the majority of the initial work directed toward the 
challenges of cigarette smoking and alcoholism (Annis & Davis, 1988; DiClemente, 
1981; DiClemente, 1986; DiClemente, Carbonari, Montgomery, & Hughes, 1994; 
DiClemente, Fairhurst, & Piotrowski, 1995; Condiotte & Lichtenstein, 1981; Rollnick & 
Heather, 1982; Yates & Thain, 1985). With regards to substance use disorders, self-
efficacy is hypothesized to determine whether, and under what circumstances, individuals 
will experience a relapse (DiClemente, 1986; Maisto et al., 1999; Marlatt & Gordon, 
1985).  
 Numerous studies have shown that self-efficacy beliefs (often referred to as 
abstinence self-efficacy or drug-refusal efficacy) are highly correlated with successful 
outcomes in abstaining from substance use. The research on the self-efficacy to resist use 
of substances has been hypothesized as a mediator of environmental influence and 
behavior (Maisto et al., 1999) and is shown to be one of the strongest and most consistent 
predictors of future use in trials with adult marijuana users (Litt et al., 2005).  
 Among a group of alcohol and drug-addicted patients in residential treatment, a 
high level of self-efficacy at the time of discharge was the strongest predictor of one-year 
abstinence (Ilgen, McKellar, & Tiet, 2005), while others (Ilgen, 2006) found that 
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enhanced self-efficacy predicted abstinence from drinking for up to three years, with 
patients possessing less self-efficacy as being more likely to relapse. The research for 
self-efficacy as a predictor of treatment outcomes (Kadden & Litt, 2011) has been 
overwhelmingly positive, and this has led to a greater focus on fostering higher levels of 
self-efficacy among substance-abusing patients in addiction treatment centers.  
 In studies of adults, ratings of self-efficacy have been found to predict drinking 
behavior (Annis & Davis, 1988; McKay, 1993), and the efficacy beliefs of adult smokers 
revealed that those in an active state of change reported higher levels of self-liberation or 
willpower (Prochaska et al., 1992). For the most part, it appeared that people with higher 
levels of self-efficacy beliefs begin to regulate and control their choices of the actions in 
which they preferred to participate, and demonstrated self-control in high-risk situations. 
Even in high-risk situations that would typically lead to drug use, possessing self-efficacy 
reduced the risk of patients returning to substance use (Marlatt & Gordon, 1985).  
 In Bandura’s (1999) view, people with high self-efficacy benefit more from 
treatment for substance abuse, mounting the effort needed to change and learning the 
skills needed to succeed. Bandura (1999) held that beliefs in self-efficacy affected every 
aspect of positive change, including initial efforts to overcome substance abuse, reaching 
sobriety, recovering from possible relapses, and finally maintaining a “drug-free life” (p. 
214). Regardless of the source of motivation to relapse—a negative emotional state, 
environmental temptations, promises of pleasure, or simply finding life too boring—self-
efficacy plays an active role, determining whether someone suffers a relapse or further 
adapts (Bandura, 1999). This suggests that adolescents with higher degrees of self-
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efficacy could also benefit from continuing treatment in a residential treatment setting.  
 The strong relationship between self-efficacy beliefs and substance use outcomes 
has been confirmed in numerous studies. In a review of 63 published papers and findings 
from 51 unique alcohol disorder treatment outcome studies from 1977 to 2005, Adamson 
et al. (2009) found self-efficacy to be the most consistent predictor of future abstinence. 
Other studies on alcohol treatment outcomes also found that higher levels of self-efficacy 
were predictive of improved outcomes for both males and females in both inpatient and 
outpatient treatments, for one year with up to three years of follow-ups (Burling, 1989; 
Greenfield et al., 2000; PMRG, 1997; Rychtarik, 1992). As a result of the plethora of 
positive findings, many evidence-based treatments have been explicitly designed to target 
and improve levels of self-efficacy (Witkiewitz & Marlatt, 2004).  
 Seeking to identify the factors predicting positive increases in efficacy and 
improved outcomes in alcohol disorder treatment, McKellar et al. (2008) examined 420 
adult individuals over the course of 16 years. They identified several factors that 
influenced self-efficacy: decreasing depression, reducing substance use, controlling 
impulsivity, and participating in Alcoholics Anonymous’ 12-step program. Interestingly, 
the study also found that long-term outcomes showed greater increases in efficacy for 
women, as well as those who pursued higher educational achievements. The authors 
suggest that the latter result may be an effect of the process of obtaining higher 
education; that is, education facilitates the ability to consolidate gains over the long 
term—obviously, this is an asset that adolescents are unlikely to possess. They could, 
however, benefit from the presence of associated improvements in self-efficacy available 
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through the social support participants received through 12-step fellowships (McKellar, 
2008). This suggests that like-minded social support while making positive changes 
actively reinforces the attainment of self-efficacy. The authors advise that these findings 
have practical applications during treatment; that is, efforts to improve a patient’s self-
efficacy should involve teaching problem-solving coping strategies and helping patients 
focus on long-term rewards.  
 Another important finding (McKellar, 2008) was that those who initially made 
faster progress in their addiction and substance-related problems, but still had difficulty 
controlling impulsivity, demonstrated the least ability to maintain self-efficacy gains over 
the long term. Therefore, the finding that improvements in impulsivity and social support 
resulted in greater self-efficacy suggests moderating variables for patients with impulse-
regulation disorders or deviant anti-social tendencies. Clients with common liability to 
addiction traits primarily in the externalizing disinhibition category may have greater 
difficulty maintaining positive outcomes from self-efficacy over time.  
 These considerations could point to the confounding issues of developmental 
stage and neural plasticity that adolescents possess (Dahl, 2004). While this may allow 
for more rapid recovery rates and a physical resiliency that allows them to “bounce back” 
from the effects of substance use more quickly than adults, this resilience can act as a 
double edge sword, impeding the likelihood of gaining insight into and awareness of 
future enduring physical consequences to their health from substance use (Maisto et al., 
2003; Brown et al., 2001). Instead, it may facilitate overconfidence and exaggerated 
levels of optimism, inflating confidence about risk-taking and making the idea of “just 
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one” irresistible—the inevitable result is recidivism, as suggested by (Haaga, 1992, p. 
24).  
 While most researchers have found self-efficacy to be a predictor of outcomes, 
this correlation has not been absolute or unquestioned. Wong (2004) studied abstinence 
and self-efficacy with adult cocaine-dependent clients and found that self-efficacy was 
not the best predictor of positive treatment outcomes. Measuring efficacy using the 
Situational Confidence Questionnaire (SCQ), they examined associations between self-
efficacy to resist cocaine, and future abstinence levels. This study actually discovered that 
higher SCQ scores were more highly correlated with abstinence from cocaine, than 
efficacy. They also examined whether clients’ greater durations of abstinence would 
demonstrate higher SCQ scores. They found that early efficacy was a significant 
predictor of later efficacy but not of later abstinence, whereas early abstinence was a 
significant predictor of both abstinence and efficacy. Although this study was performed 
in a non-residential outpatient setting, and no direct support for self-efficacy and 
outcomes was determined, their findings do provide support for the traditional 
justification for residential treatment, as greater durations of abstinence from the drug 
produced greater levels of confidence-building, increased overall confidence scores, and 
inevitably results in decisions to avoid using the drug.  
 While there is wide acceptance of the position that having high levels of self-
efficacy is an important determinant of outcomes in drug abuse treatment (Bandura, 
1999; DiClemente, Fairhurst, & Piotrowski, 1995), the findings reported by Wong (2004) 
suggest that experiencing early success in abstaining from drug use may be an even more 
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fundamental determinant. As reported days of abstinence, and not efficacy, was the 
stronger predictor of future abstinence in cocaine-abusing clients, these findings suggest 
that other crucial considerations influencing treatment outcomes may be overlooked. 
While further inquiry into this possibility falls outside the scope of the proposed study, it 
is an outcome that supports structured treatment for adolescents, and suggests important 
questions for future research. 
 The centrality of self-efficacy theory to my questions for investigation 
necessitates a more complex understanding of the concept: for instance, Bandura (2006) 
argued that domain-specific self-efficacy is more relevant to any specific behavior 
outcomes than global efficacy. He reasoned that we cannot do everything well, and 
instead we selectively cultivate self-efficacy in certain domains. As a result, levels of 
self-efficacy are likely to vary depending on the domain. Since it is possible that some 
individuals are strong in self-efficacy for a certain behavior while being weak in another 
(Bandura, 2006), drug-specific self-efficacy should likewise be carefully considered. In 
other words, youth may have different levels of drug-resistance self-efficacy depending 
on the type of substance that is offered. This makes sense, as youth initiate use of 
substances at different rates (Kosterman, 2000), and thus have more or less experience 
with various substances. One recent factor-analytic study supports this theory, finding 
drug-specific self-efficacy for alcohol and marijuana resistance (Carpenter, 2009). It may 
be, for example, that youth who have positive attitudes toward substance use, and possess 
experience with both offers and refusals, may engage in substance use despite having 
high refusal skills.  
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 Results from evaluating the influences of discharge status and during-treatment 
change among young adults (Kelly et al., 2012) also demonstrates that self-efficacy is 
still an important predictor of short-term abstinence outcomes, and self-efficacy 
measured at various points over treatment has been consistently associated with 
abstinence outcomes (Adamson et al., 2009; Connor, 2011; DiClemente, Marinilli, Singh, 
& Bellino, 2001; Long, 2000; McKay, 2001; Morgenstern et al., 1997; PMRG, 1997). 
Thus, evidence suggests that self-efficacy also represents a clinically meaningful 
indicator for monitoring progress and potential during early recovery (Kadden & Litt, 
2011).  
Drug Refusal Self-efficacy during Adolescence  
 Burleson and Kaminer (2005) found that in a sample of 88 adolescents in an 
outpatient setting, the higher the self-efficacy (utilizing the SCQ), the more likely the 
subsequent abstinence. They also noted that positive self-efficacy was associated with 
higher rates of abstinence and more positive outcomes regardless of treatment condition. 
These findings support the idea put forward by Bandura (1999) that those with higher 
self-efficacy will benefit more from additional treatment. However, Bandura (1999) does 
caution that studies of self-efficacy cannot be isolated outside of the social relations 
within which they exist. A negative emotional and social life can erode efficacy and self-
worth. Depression (a genetic liability) is known to undermine academic performance 
(Nolen-Hoeksema, 1986), and students who doubt their own efficacy tend to gravitate 
towards peers who devalue academic pursuits (Bandura, 2006). Disengagement from 
academic activities often means engagement in a pattern of problem behaviors that 
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jeopardize the prospects of a successful future (Donovan, 1991; Bandura, 2003; 
Patterson, 1984).  
 Walker et al. (2011) examined the effects of perceptions and refusal self-efficacy 
on marijuana-using outcomes, to understand what factors most influenced adolescent 
substance abuse. They reported that drug refusal self-efficacy was negatively associated 
with negative outcomes. Drug refusal self-efficacy was positively associated with 
reductions in frequency of use, controlling use, and reducing the risk of temptation to use. 
However, in their discussion, the authors point out that drug use promotes associating 
with others who use more and approve more of using. Refusal self-efficacy beliefs may 
be influenced more by the peer network than by personal beliefs. This is highly relevant 
for adolescents, who during this developmental period shift the locus of their behavioral 
assessments and acceptance of values from parents to peers (Sales, 2013). This further 
supports the premise and importance of utilizing further residential treatment for 
adolescents, which theoretically would structure the influence of peers while enabling 
continued recovery, as well as guiding the development of improvements in refusal self-
efficacy and regulatory skills.  
 Schell et al. (2005) examined drug refusal self-efficacy, extracting its role 
amongst adolescent treatment needs beliefs and patients’ substance problems, to indicate 
its value for treatment utilization. Using data from the Global Appraisal of Individual 
Needs (GAIN), refusal self-efficacy beliefs were derived using the GAIN’s five-item 
refusal self-efficacy index. These items assess adolescents’ self-efficacy to refuse drugs 
in various situations at home, work, and school, or when friends were using or people 
  
66 
around the adolescent were using. Additional GAIN items correlated highly with the 
refusal self-efficacy items and had noticeably coinciding content— “It will be hard for 
you to resist drugs where you currently live, work, or go to school,” and “Your old 
friends may try to get you to drink or use drugs again,”—these questions were included to 
create their scale. This scale showed adequate internal reliability (Cronbach α = 0.74), 
and was highly stable across the 5 waves of data in which the adolescents were followed 
throughout treatment episodes over 12 months.  
 Using two separate samples of adolescents in the study, 476 in residential 
treatment and 519 in outpatient treatment, data was collected to examine the temporal 
nature of the relations between refusal self-efficacy, perceiving a need for treatment, 
substance related problems, and actually utilizing treatment. This study assumed that 
these processes could be approximated by effects that repeat over time. For example, the 
expected component of change in refusal self-efficacy per unit of treatment dose in the 
prior period is assumed to be constant when predicting 6-, 9-, and 12-month 
measurements of refusal self-efficacy. Using a cross-lagged analytic framework allowed 
the researchers to evaluate for causal relationships. They found that low drug refusal self-
efficacy was correlated with higher levels of treatment utilization. They found that low 
refusal self-efficacy presaged higher levels of substance abuse problems. They also found 
that adolescents who believed they had a high need for treatment and those who received 
larger doses of treatment decreased their drug-related problems.  
 These findings corroborate Maisto’s (2011) position that adolescents have little 
intrinsic motivation to change substance abuse, and external forces are often needed to 
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motivate and sustain abstinence oriented behaviors. The low substance-resistance 
efficacy decreased abstinence, which increased substance-related problems, and the 
problems became a very concrete external force, compelling a form of insight into the 
perceived need for treatment. The ensuing higher dose of treatment then decreased the 
substance-related problems.  
 Is it possible that adolescents with high drug refusal self-efficacy may still 
recognize the threat of their own common liabilities to addiction, and also recognize the 
benefit of residential treatment utilization where influences will be securely directed 
toward continued abstinence? Bandura (1999) did argue that those with higher refusal 
self-efficacy would also have greater impetus for change, and be capable of getting the 
most out of treatment.  
 Burleson and Kaminer (2005) found support for this claim as well, positing that 
adolescence may represent what Litt (2005) described as a critical period, wherein self-
efficacious people may enter treatment at a time when they can actually capitalize on the 
treatment provided. However, Haaga and Stewart’s (1992) finding that modest self-
efficacy, and not high self-efficacy, leads to the best rates of abstinence among smokers 
challenges this idea, while presenting a viable threat for adolescents’ ability to abstain 
since higher levels of initial overconfidence and lower insight might undermine decisions 
to sustain initial abstinence through the option of a structured residential treatment.  
 Furthermore, research findings continue to demonstrate that continuing-care 
treatment approaches, outside of the safety of structured residential treatment programs, 
are more effective only for low- to moderate-severity addiction clients discharged from 
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residential treatment (Dennis, 2014). It has been found that even after several weeks of 
residential treatment, most adolescents were still on the fence about refraining from 
substance use (Wei, 2011). Since achieving positive change appears to be imperative in 
alleviating the burden of substance use disorder (Dennis, 2014), knowledge of how 
differing psychological and genetic characteristics might interact to influence this 
sustainable change is important. Understanding the power and ability of drug refusal self-
efficacy to moderate the behavioral-genetic characteristics of CLA may clarify which 
client types would most benefit from which treatment modalities, and what form of 
continuing services should take.  
 To exemplify this point, Walker et al. (2011) noted that refusal self-efficacy might 
be unduly influenced by the adolescent peer network. Adolescents who return to their 
community after only a few weeks of stabilization are at greater risk, as previous peer 
influences will still be present after just a short time in treatment. Those who enter 
residential programs might have a greater opportunity to maintain abstinence, being in a 
more protective environment with controlled influences that can help them continue to 
halt the assault of substance use, allowing healing within their neuronal networks while 
securing increased opportunities for time and practice in developing necessary coping 
skills for healthy living.  
 Schell et al. (2005) found that low refusal self-efficacy to resist drugs was 
associated with higher levels of treatment. This is not surprising as those without the 
ability to resist substances may seek the additional support and structure needed to enable 
sobriety. But what about those patients who do not enter further treatment? It seems 
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natural that a high perceived drug refusal self-efficacy would influence that decision, but 
what about the unnaturally high recidivism rate? There is a definite gap in the literature in 
this area, particularly for adolescent populations, and a further gap exists in theory and 
research regarding drug refusal self-efficacy’s influence on genetic mechanisms that 
could affect outcomes via general neurobehavioral mechanisms, irrespective of drug class 
or treatment modality (Hendershot, 2011).  
Summary of Self-Efficacy  
 What we have learned from the research on self-efficacy’s power against 
addiction is that it is itself a product: it is a product of experience and the resources 
available to an individual. While it has been demonstrated that self-efficacy can influence 
actions independently of past behavior, and that perceived self-efficacy can predict future 
behavior better than past performance, the evidence for efficacy has not been all positive. 
It has been found in some clients that moderate efficacy was in fact better correlated with 
success than high efficacy or low self-efficacy.  
 Refusal Self-efficacy has consistently been one of the most powerful indicators of 
outcome from addiction treatment. It is almost always correlated with successful 
outcomes, as well as greater levels of abstinence. Although duration of abstinence is a 
more robust predictor of refusal self-efficacy and outcome, low refusal self-efficacy has 
been found to a high predictor of negative emotional states and outcome. Although 
refusal self-efficacy is one of the greatest predictor of abstinence at one year, enhanced 
refusal self-efficacy predicted abstinence from drinking for up to three years, also 
revealing lower self-efficacy as significantly related to relapse.  
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 Studies of refusal self-efficacy within the adolescent population have likewise 
indicated that higher refusal self-efficacy was correlated with greater levels of subsequent 
abstinence, while low refusal self-efficacy was associated with lower self-esteem, 
depression, and greater substance use problems. However, lower refusal self-efficacy has 
also been associated with higher levels of choosing further treatment, which is a positive 
step for continuing care. While this may indicate the coercive influence of caretakers and 
other stakeholders in the adolescents’ life, e.g. schools, drug courts, police officers, as 
youth are generally known to resist treatment, it was also noted that adolescents who felt 
the need for treatment generally and received it had reductions in use and reductions in 
substance related problems.  
 However, just as environment is required to produce genetic manifestations of 
disease or ability, additional resources are required to support psychological constructs. 
Adolescent refusal self-efficacy beliefs have been found to be unduly influenced by the 
peer network. Caretakers are usually in control of adolescent resources including the 
environment they may return to after treatment. Regardless of refusal efficacy beliefs, 
opportunity may trump ability. Youth whose peer groups maintain a positive view of 
substances may engage in use regardless of possessing high refusal efficacy skills. 
Therefore, while refusal self-efficacy grows stronger in the absence of substance abuse, 
in adolescence, it is also moderated heavily by innate desires for peer acceptance, and an 
immature regulation system focused on the immediacy of the moment.  
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The Role of Social Capital  
 It is evident from the research presented in the previous section that there are 
many factors at play in treatment outcomes. The biological complications of development 
and the tendency for like-minded peers to flock to each other indicate the heavy-handed 
influence and importance of environment. In this section, a long-standing theory 
borrowed from criminology research, called the life-course perspective which has 
illuminated additional indicators for successful remission from addiction will be 
discussed. The two most frequently seen factors present for making the change from 
active drug user to abstaining from substances, and having a new productive life are 1) 
First having attended formal treatment, and 2) Having access to a certain level of social 
connectedness and resources known as social capital.  
 The life course perspective of human behavior recognizes the importance of time, 
timing, and the chronological developments that occur during an individual’s lifetime 
(Hser et al., 2007). The life course perspective has a long history in the health, and public 
health fields, particularly in the social sciences (Elder Jr, 1985; Lynch & Smith, 2005). 
Research findings have generally shown that patterns of lifetime drug use and related 
problems are extremely diverse (Hser et al., 2007). Severe or dependent users tend to 
persist in their drug use, and often, with repeated cycles of cessation and relapse 
occurring over substantial periods of their life span. It has long been argued that current 
treatment research views addiction as distinct acute cases or episodes, and that a 
“longitudinal, dynamic approach” (Hser et al., 1997, p. 543) such as is found within the 
life course perspective would be more useful.  
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 Broadly, life course theory links individual biography to historical, geographical, 
and structural context in an effort to understand social change and individual 
development (Hser et al., 2011). Adolescence is considered one of the most critical 
periods of change in the life course, with events literally altering developmental pathways 
during this time. A central tenet of life course theory, particularly in adolescent substance 
abuse, is that the timing of a transition sets its developmental impact (Elder, 1986; Elder, 
1998). Life transitions (e.g., entry into first grade, moving, divorce of parents) are always 
a part of social trajectories that give them a distinctive sense and shape; however, 
historical forces shape the social trajectories of family, education, and work, which in 
turn influence individual behavior and differing lines of development. By focusing on the 
trajectories across individuals’ lives and the ways in which those patterns are shaped by 
the broader historical context and social structures, the life course perspective offers an 
extended framework that allows for identifying critical moments in the development of 
drug use trajectories, the events contributing to persistence or change during the life span, 
and analytically ordering the events that occur during that course (Hser et al., 2007).  
 The major thesis of life course theory—potentially relevant to the life course 
framework applied to drug use with adolescents—is that “social capital” and “turning 
points” are important concepts in understanding processes of change (Sampson & Laub, 
2005). The life course perspective also increases our understanding of the trajectories of 
drug-dependent adolescents who participate in social service systems including addiction 
treatment, mental health services, criminal justice, child welfare, and primary pediatric 
services. Interactions with these social systems can trigger turning points for some 
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adolescents, which suggest the potential for social services to identify, intervene, and 
introduce new possibilities, to generate desirable change for substance-abusing 
adolescents.  
 Another study (Scott, 2011) found support for a life-course, continuing care 
model, in examining the mortality rates and factors that led to abstinence in a sample of 
highly marginalized substance users on the west side of Chicago over a period of nine 
years. Scott’s (2011) findings, which contradicted the current acute model approach to 
addiction treatment, indicate that treatment readmission within 6 months from initial 
treatment episode was associated with greater abstinence, whereas treatment readmission 
after 6 months was associated with greater mortality. These findings lend justification for 
more aggressive screening, early intervention, adequate initial treatment, ongoing 
monitoring, disease management skills, and better linkage to recovery support services 
and mutual aid groups that help sustain recovery while increasing social connections and 
the resources that make for social capital.  
 A long history of research has shown that family structural conditions (e.g., 
poverty, large family size, and residential mobility) and family social processes (e.g., 
inadequate supervision, inconsistent/threatening discipline styles, and weak parental 
attachment) are strong predictors of adolescent delinquency (Sampson & Laub, 2003). It 
has also been argued that when a child's exposure is compounded with negative family 
conditions, life-course-persistent offending is most likely to occur (Moffitt, 1993). In this 
life course perspective, development is conceptualized as the constant interaction 
between individuals and their environment, coupled with purposeful human agency and 
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what has been termed in biology as "random developmental noise" (Lewontin, 2000, pp. 
35–36) occurring at the cellular level.  
 The recognition of developmental noise implies that "the organism is determined 
neither by its genes nor by its environment nor even by interaction between them, but 
bears a significant mark of random processes" (Lewontin, 2000, p. 38). Thus, as neither 
agency nor structural location can by itself explain the life course of crime (Sampson & 
Laub, 2005) or addiction, it is important to note that an event does not universally lead to 
a turning point or a change in the same direction, and mere possession of higher levels of 
recovery or social capital (SC) will not necessarily result in seeking treatment (Hser et al., 
2007).  
 There have been many ways in which SC has been examined, conceptualized, and 
researched. However, a much more specific perspective is in order, considering the needs 
of adolescents in addiction treatment. The Environmental Strengths Index looks at the 
three primary domains of an adolescent in which support can be offered to aid in the 
transition from actively using to actively recovering. These domains represented as the 
home life with family interactions, the school life, or working life of the adolescent, and 
the social arenas currently present for that youth. This index will be utilized to measure 
social capital. And as prior research has shown that both social support and refusal self-
efficacy may influence the treatment outcomes for individuals in substance abuse 
treatment (DiClemente, 1986; Greenfield et al., 2000; McKay, 2003), the implications for 
examining these factors and correlations with adolescents seeking treatment are clearly 
worthy constructs to explore.  
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Summary of the Current Literature  
 The genetic-behavioral findings and the research in the substance use-disorder 
field independently identified that neurological aberrations that indicate disorders like 
anxiety, ADHD, conduct disorder, and/or oppositional defiant disorder, and which often 
express themselves in addiction, most always precede the actual initiation of substance 
use (Conway et al., 2010; Vanyukov et al., 2003a). Since addiction, like many other 
genetic potentialities, require environmental stimulus to be galvanized, the use of any 
mood-altering substance should have the potential for addiction’s ultimate realization in 
an individual. Therefore, addiction itself is not dependent on the presumed severity of the 
initial drug used. This has led to the myth of a gateway drug theory, and the belief that 
certain drugs are safer or softer than other drugs. Currently, therefore clients switch 
addictions from one substance to another. Whether it is marijuana that leads to heroin 
addiction or heroin use that leads to alcoholism, likewise relapsing to addiction, it is not 
solely reliant on avoiding a particular class of drugs once addiction has already been 
activated and established.  
 Formal treatment episodes have been demonstrated effective at helping clients to 
achieve remission from addiction. Refusal Self-efficacy beliefs, a client’s thoughts about 
their ability to resist relapsing to addiction, is one of the most consistent indicators of 
positive outcomes for treatment, but it is not the only important factor. The 
developmental challenges, impulsivity, and general malaise of adolescents reinforce the 
necessity of social resources and available alternatives to provide more appealing 
opportunities to assist abstinence and efficacy.  
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 Since the length of initial time in treatment has been solidly correlated with more 
positive outcomes (Dennis et al., 2005; Dennis et al., 2007; Dennis, 2014; Kelly, 2010; 
Kelly et al., 2012; Hser et al., 1997; Hser et al., 2001), and according to appropriate 
continuum of care standards, patients should step-down from hospital level care to the 
less restrictive yet still well-structured environment of residential treatment (American 
Society of Adiction Medicine, ASAM, 2001).  
 Further, the literature on outcome factors identify the following:  
● More positive outcomes are associated with higher refusal self-efficacy.  
● Duration of abstinence is associated with positive outcomes regardless of 
efficacy beliefs. While continued, abstinence allows for the improvement of 
efficacy beliefs; efficacy beliefs alone are not always correlated with positive 
outcomes or abstinence.  
● Moderate efficacy as opposed to high efficacy has been more strongly 
correlated with future abstinence, suggesting an overconfidence effect that leads 
to future risk-taking around substances. This is relevant for adolescents who 
naturally tend to over-exaggerate abilities.  
● In adolescence, the social influence of peers affects refusal efficacy, often 
acting as a stronger influence on outcomes; however, drug refusal self-efficacy 
has still been associated with reductions in use, whereas low refusal self-efficacy 
is associated with continued drug use, recidivism, and poorer outcomes.  
● Although lower refusal self-efficacy to resist drugs measured among 
adolescents has been correlated with poorer outcomes, it has also been correlated 
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with further treatment utilization, which is associated with positive outcomes. 
 The self-efficacy research shows great promise in assisting developmental 
approaches to affect the treatment of this disorder; many questions regarding the period 
of adolescence remain. Can low refusal self-efficacy be balanced with a keen insight or 
foreknowledge and a desire for safeguarding abstinence, as Burleson and Kaminer’s 
(2005) study might suggest? Might this be a demonstration that some adolescents are 
capable, despite the developmental limitations of a brain in the midst of construction, to 
seek greater treatment utilization at a time when they can capitalize on it? Or does this 
merely demonstrate that external pressure from parents, schools, and courts, positive 
indicators themselves, have led to this decision?  
 Surprisingly outcome indicators in addiction have rarely been consistent across 
drug of choice, gender, or duration of use. However, when looking at the current body of 
literature on the common liabilities for addiction, and treatment of addiction in adolescent 
populations, two main categories of findings emerge: genetic phenotypes indicate future 
behavior as a combination of genetic predisposition, and opportunity. This is supported 
by the finding that even the powerful effect of duration of abstinence, and achieving 
initial success, was undermined by having difficulty controlling for impulsivity (a genetic 
phenotype). This expresses a severe challenge for adolescents, who are in a state of 
constant flux, a developmental emotional roller coaster, wherein the supports they long 
for, their peers, are many times a known negative influence on positive outcomes. 
Therefore, by implication, the presence of constructs that would most consistently 
moderate addiction would be the constructs that support a positive belief in change, while 
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controlling opportunity such as provided in residential treatment.  
 As previous research has demonstrated that low refusal self-efficacy among 
adolescents is correlated with decisions to further their treatment (Schell et al., 2005), 
resulting in longer durations of substance abstinence, how does high refusal self-efficacy 
manifest alongside the influence of these inherent, observable CLA traits? Would the 
self-efficacy to refuse drugs, a psychological construct, have enough power to moderate 
the influence of these CLA effects, or are the influences of social capital, an 
environmental resource, necessary to make abstinence more appealing?  
Limitations  
 The findings on the positive effects of refusal self-efficacy may not be 
generalizable across all populations. Many of the inconsistent findings in the self-efficacy 
studies may be related to sampling methods. Many of these studies have been performed 
at varying levels of care, i.e. outpatient vs. inpatient residential, which may have affected 
the participants’ responses. Further, these studies chose many different instruments for 
measuring levels of efficacy. While different methods raise concerns about the validity 
and reliability of the instruments, it also makes it difficult to compare the results across 
population studies. This study will attempt a careful analysis of outcome interpretations 
due to a lack of generalizability.  
Rationale for the Current Study  
Adolescents are a very difficult population to treat and study. The dearth of 
research and the lack of consistent findings for positive outcome indicators demand 
additional attention. With an illness as complex as addiction which manifests as a 
construct only when conditions such environmental, genetic, and even random on the 
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cellular level are present, we must not make sweeping claims. The nature of efficacy as a 
psychological construct will likely present differently based on identity consolidation, 
development, and experience. With such a large number of addicted adults’ reporting that 
they started using in childhood, and many of these studies did not parse out for age of 
initial use, there is no way of determining how long addiction has been influencing each 
client’s perceived refusal self-efficacy. Would self-efficacy have been consistent across 
clients with differing durations of use? Although the efficacy research with adolescent 
outcomes is very similar to that of adults, there may be additional factors to consider; the 
nature of peer influences on efficacy reports during treatment, experiences with previous 
treatment episodes, the presence of developmental interactions such as new hormones, 
and the differing drives present due to age differences may all have affected the reported 
efficacies of the respondents.  
The current data on positive indicators for adolescent addiction outcomes have 
been flawed through inconsistent approaches that may have had dissimilar populations, 
measurement methods, or adolescents at differing levels of development. Current 
diagnostic procedures for identifying adolescent addiction may be insufficient, as ever-
changing developmental interactions may alter display of withdrawal, tolerance, or even 
the effects of the substances. Therefore, alternative approaches are needed for isolating 
subgroups more amenable to treatment approaches. In addition, identifying ways to parse 
specific subgroups is an important concern for treatment that may determine which 
psychological constructs, or social capital influences have the most promise for beneficial 
outcomes.  
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 Purpose of Study:  The purpose of the present study is to identify the common 
liability to addiction in a sample of adolescents currently seeking treatment for addiction, 
and determine how previously identified psychological and environmental variables 
(Social Capital and Refusal Self-Efficacy) are related to treatment choices. Interactions 
amongst the independent variables will also be examined.  
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CHAPTER THREE: METHODS  
Introduction  
 This chapter provides a detailed explanation of the procedures used in this study. 
Specifically, it outlines the selection of participants, the instrumentation, and the analysis 
of data. The chapter is divided into three sections: purpose, participants, and settings; 
procedures and measures; and the method of analysis for the data.  
Purpose of the study  
 The purpose of the study was to investigate the relationship among the Common 
Liability to Addiction (CLA), refusal self-efficacy, social capital, and the use of treatment 
services among adolescents with substance use disorder. To add to the literature, in the 
study, the CLA was catalogued among a sample of adolescents currently in treatment, 
and how this variable influenced treatment outcome decisions was determined. Alongside 
the CLA, the additional resources of social capital, and drug-refusal self-efficacy were 
examined to determine if these factors possessed any significant influence on moderating 
adolescent treatment decisions. In order to establish the required sample size, a power 
analysis was conducted with 80% power predicting an effect size of .35 (medium effect). 
This power analysis indicated a required sample size of 67. The next section describes the 
procedure for recruitment of participants and the study’s instruments.  
Participants  
Demographic information for each participant was gathered from an existing data 
set provided by Chestnut Health Systems and included the following: gender, ethnicity, 
and drug of treatment. The data set also included family history of alcohol or drug abuse, 
family history of mental illness, and living situation. In addition, age of onset and current 
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age were combined to create a new variable looking at duration of use and number of 
previous treatment attempts (see Table 1).  
Thirty-one percent of the participants were female, and 69% were male. Seventy 
five percent of the sample was Caucasian, 7% was Hispanic Latino, 6% was African 
American or Caribbean islander, and 13% was bi or multi-racial. Reports for substances 
used had 49% of participants reporting marijuana as their drug of choice, while 20% 
reported alcohol, 17% reported opiates, and 9% reported other drugs of choice. The drugs 
of treatment were similar at 38% being treated for marijuana, 21% alcohol, 23 % opiates, 
and 10% other drug use.  
Family histories of alcohol and drug use were very similar at 74% and 75%, 
respectively, while family history of psychological issues was reported at 59%. As far as 
current living situations were concerned, 21% lived with parents living together, 41% 
lived with one parent (even if living with step parent), 14% lived in a foster home, 6% 
lived with another relative, 10% had separated shared custody, 3% had other living 
situation, and 6% of the population was 18. 
Of the sample of adolescents currently receiving treatment in this study, the 
youngest was 13 and the oldest was 18, with a mean age of 16.21. Most of the 
participants were either 16 (N = 20; 28%) or 17 (N = 29; 40.8%) years of age.  
Age of onset of participants’ addictions ranged from a low of age 7 to a high of 
age 16, with a mean onset age of 12.49. Over half of the participants (N = 41; 57.5%) 
reported an age of onset between 12 and 14 years.  
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Table 1 
Sample Characteristics 
Gender Age 
 Female 31%  Range = 13–18 
 Male 69%  M=16.21 
    
Race/Ethnicity Age of Onset 
 Caucasian 75%  Range = 7–16 
 Hispanic/Latino 7%  M= 12.49 
 Afr. Amer./ Carib. Is. 6%   
 Bi/ Multi-racial 13%   
    
Drug of Choice Drug of Treatment 
 Marijuana 49%  Marijuana 38% 
 Alcohol 20%  Alcohol 21% 
 Opiates 17%  Opiates 23% 
 Other 9%  Other 10% 
 
Duration of use was calculated by subtracting age of onset from current age. 
Duration of use values ranged from 1 to 8, with a mean of 3.71 years. Participants most 
commonly reported 3 (N = 16; 22.5%) or 4 (N = 17; 24%) years of use. Participants also 
reported on the total number of treatment attempts they had made, with 66.2% (N=47) 
reporting that this was their first treatment episode, and 24% reporting one prior 
treatment episode. The remaining participants (N=7, 9.8%) had been to treatment 
between 2 and 5 prior times.  
Setting  
 Admission to the facility required a diagnostic finding of substance use disorder 
based on the current American Society of Addiction Medicine criteria (ASAM, 2001), as 
identified by referral from a crisis team, a hospital, another substance abuse facility, or 
direct admittance via the state-funded insurance company: the Massachusetts Behavioral 
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Health Partnership (MBHP). The facility accepts patients regularly from all areas in 
Massachusetts, as well as surrounding states, with the majority of patients hailing from 
areas in Western Massachusetts, Brookline, Boston, and Cape Cod. The ages of patients 
were restricted to 13–17, although an 18-year-old patient was admitted if still enrolled in 
high school.  
 The setting of the treatment center was a short-term, 2-week to 1 month, 24-bed, 
co-ed inpatient stabilization program. As an Evidence-Based Program (EBP) treating 
adolescents, the facility is recognized by the Substance Abuse and Mental Health 
Services Agency (SAMHSA), and is licensed, monitored, and regulated, by The Joint 
Commission Accreditation for Health Care Organizations (JCAHCO), as well as the 
Massachusetts Department of Public Health (DPH). The primary mission of EBP 
treatment for adolescents is to prepare them for continuing treatment with successful 
outcomes indicated by remaining within a continuum of care; choosing to support 
abstinence with additional treatment services (Winters, 1999). The participants selected 
from the subset of GAIN data consisted of the 71 clients who entered treatment during 
the second half of 2011, and were included in the Assessment Building System 
collaboration between Chestnut Health Systems and the treatment facility. This 
collaboration allows data sharing of treatment facility records to Chestnut Health 
Systems, as well as utilization of the Assessment Building System program (ABS). This 
web-based arrangement is a real time, HIPAA compliant, diagnostic system allowing for 
detailed clinical reports, summaries, and ASAM treatment recommendations immediately 
upon completing an assessment. 
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 It is important to understand that the choices made by the participants during this 
study were not made in a vacuum. While the federal law makes the choice of the person 
attending treatment (Confidentiality of Alcohol and Drug Abuse Patient Records, 2010), 
rarely do children have this much autonomy when it comes to important decisions that 
will undoubtedly affect their future. Parents, probation officers, and collateral workers all 
play a role in heavily influencing the final choice of these adolescents seeking treatment. 
In addition, it is important to note that this data is from 2011 and the substances 
most commonly used then may differ from today. In 2011, according to the Center for 
Addiction and Substance Abuse Research at Columbia University, Alcohol was the most 
preferred addictive substance with 72.5% of high school students having drunk alcohol. 
46.3% have smoked cigarettes, 36.8% have used marijuana and 14.8% have misused 
controlled prescription drugs including opiates. Of the adolescents who have used more 
than one substance 65.1% reported to have been poly-drug users, and 46.1% admitted 
they were current users of addictive substances. 
Procedures  
 After seeking and obtaining approval from the Institutional Review Board of 
Boston University, a subset of data collected from June through December of 2011 was 
analyzed in this study at an adolescent drug and alcohol abuse treatment center in 
southeast Massachusetts. Data for this study came from two sources: The Global 
Appraisal of Individual Needs (GAIN), which is licensed by Chestnut Health Systems, 
and the treatment facility itself, which released the treatment outcome decisions of the 
patients for the purposes of this dissertation. These data sets were then imported into the 
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software application IBM SPSS (Statistical Package for the Social Sciences, version 20) 
for data analysis. The statistical processes applied to analyze the data were descriptive 
analyses, preliminary analyses, and ordinal regression. There were two cases of missing 
data with outcome choices not recorded and these were removed from the study. For the 
self-efficacy scale those participants who reported an “I don’t know” which existed 
outside of the binary scale of yes =1 and no=2, the questions’ answers were determined 
to be no=2 based on the literature (Dennis, 1999; Dennis, 2000). 
Measures  
 All of the data utilized in this study, except the adolescent discharge choices, were 
culled from subscales within the Global Appraisal of Individual Needs (GAIN; Dennis, 
2003). The discharge decisions of patients were provided by the facility for purposes of 
this dissertation and as part of a dedicated and continuous process of program 
improvement. The scales from the GAIN (Dennis, 2003) used in this study were the 
Refusal Self-Efficacy Scale (RSE), the Environmental Strengths Index to measure Social 
Capital (SC), and the Common Liability to Addiction Scale (CLA) created from GAIN 
questions used in the Hicks et al. (2012) study with the Minnesota Twin and Family data, 
to replicate CEDAR’s original scale (Vanyukov et al., 2003b). Each of these subscales is 
described below. The outcome data set of the Continuing Care Choices of each patient, 
made after this acute treatment episode, made up the dependent variable. This variable 
was considered to be ordinal in nature, with each choice representing increasingly higher 
levels of expectations, responsibility, and commitment from patients. The ordinal 
measure scale scored least favorable outcomes as the lowest ranked choice, Non-
  
87 
Compliance (0), up to the most favorable condition represented by the more statistically 
beneficial choice of residential treatment (4).  
Refusal Self-Efficacy (RSE)  
 Self-efficacy to resist drugs was measured using the GAIN Refusal Self-Efficacy 
Scale (RSE) as modified by Schell et al. (2005). In addition to the five questions within 
the GAIN SES index, Schell et al. (2005) used this scale to examine the relationship with 
treatment, relapse, and continuing care, finding two additional GAIN items with 
substantially overlapping content to correlate very highly with the refusal self-efficacy 
items. This seven-item scale measures the cognitive, affective, and behavioral 
perceptions of efficacy and triggering influences. Participants in this sample were asked 
to answer questions focusing on how they felt about their ability to resist substances at 
school, home, work, or among old friends, as well as their perception of how difficult it 
would be to maintain their resolve for sobriety in different contexts. This classical scale 
(e.g., true false) was scored simply as the sum of the responses divided by the amount of 
questions answered. This scale has previously demonstrated internal reliability with a 
Cronbach alpha at .71 with adolescents, and good replication and internal consistency 
with adult populations at .72. The modified scale was reported in the Schell et al. (2005) 
study to have adequate internal reliability (Cronbach = 0.74), and was highly stable 
across 5 waves of data collected in the 12 months the 995 adolescents were monitored 
during treatment. The modified refusal self efficacy scale in this study had adequate 
internal reliability (Cronbach = .76). 
 For the modified RSE scale participants in the current study answered yes or no 
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about their refusal self-efficacy beliefs. The scores represented summative value, 
indicative of their current confidence; with higher scores on the RSE scale indicating 
greater levels of self-confidence about maintaining sobriety and resisting relapse in 
different situations. Per the assessment procedure and continuing care recommendations 
from the American Society of Addiction Medicine (Mee-Lee, 1996), lower scores 
suggest a higher likelihood of relapse and the need for additional assistance in daily 
living, and the need for a more controlled environment, therefore scores that included an 
“I don’t know” answer were determined to be negative (Dennis, 1999; Dennis, 2000).  
Social Capital  
 The Social Capital Scale (SC) used for this research study was based on the 
Environmental Strengths Index (Dennis, 2003) which measures assets previously 
identified in the literature as affecting levels of support (Knight & Simpson, 1996; Garner 
et al., 2008; Perry & Duroy, 2004; Ives, Funk, Ihnes, Feeney, & Dennis, 2012). Thus, the 
social capital scale (12 questions on a Likert scale) reports the presence of healthy versus 
unhealthy people that the patient has present in their environments of home, school, 
work, or social life. This scale determines the availability of positive and healthy social 
supports in the patient’s contextual lives. This 12-item summative index is based on 
positive attributes being scored positively (e.g., having family or friends in recovery), 
while the negative influences included (e.g., having friends who participate in illegal 
activities) detract from the total score. Higher values on this scale indicated the level of 
positive resources available to each client outside of treatment.  
 When the Cronbach alphas were run for the Social Capital scale we initially had a 
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non-reliable Cronbach alpha of α= .437. After removing the reverse coded items, the 
Cronbach alpha became more acceptable at α= .703. The GAIN reverse coded negative 
items and situations in the persons family, social environment and working lives that 
represent risk factors for substance abuse, thus not possessing these items was considered 
a positive attribute and thus social capital. The GAIN had not listed referential sources as 
yet being available to support the ESI scale from which the Social Capital scale was 
derived, however, since the social capital scale represents a recovery scale in which the 
positive attributes consisted of improving the negative aspects of substance use it was 
decided to keep this scale intact despite the low Cronbach alphas caused by keeping the 
reverse coded items. The ramification of removing the items would change the social 
construct scale resulting in a narrower construct and impact the nature of what is actually 
being assessed therefore it was felt that it was important to leave the scale intact. 
Common Liability to Addiction Scale  
 The Common Liabilities to Addiction (CLA) index, as used by Hicks et al. 
(2012), was used to identify risk potential for developing addiction. The CLA instrument 
allows the user to transition from a categorical measurement to a continuous 
measurement approach that weighs specific and observable, behavioral-genetic 
characteristics, i.e. questions indicating oppositional defiance and impulsivity, as 
experienced by adolescents, and estimates the probabilities for a future substance use 
disorder. The Hicks et al. (2012) CLA model demonstrated reliable predictive ability 
within numerous cohorts (Arria, Vincent, & Caldeira, 2009; Hicks et al., 2012; Kirisci et 
al., 2009; Vanyukov et al., 2009). The CLA derived for this study used 25 questions 
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selected from the GAIN that identify the same phenotypes as modeled in the Hicks et al. 
(2012) study. The CLA index was a simple summative index with the higher values of 
CLA characteristics representing the highest possible affliction.  
Continuing Care Choice Scale (CCC)  
 The aftercare treatment choices of the patients were used as the dependent 
variable in this study. Represented on an ordinal scale, the study ranked aftercare choices 
by intensity, formal structure, level of monitoring, and safety. Historically, patient 
attrition from substance use treatment programs is high. Research has shown that patients 
who dropout of treatment end up having the same outcomes as untreated clients (Stark, 
1992). Because of the serious nature of these consequences, it is always the least 
preferred outcome. At the opposite end of the scale, residential treatment (RT) 
represented the most structured and formal offering on the treatment continuum. In fact, 
one of the most successful substance use disorder treatment programs in the literature, the 
Physician Health Program (PHP), usually begins with 30–90 days in patient residential 
treatment. The PHP assists and intensely monitors substance abusing physicians and has 
demonstrated that between 70–96% of doctors maintain sobriety for a period of 5 years 
(DuPont, 2014).  
 The decision to rank adolescent after-care choices for continuing treatment 
services by intensity was determined specifically for this research study because of the 
accumulated evidence for adolescent outcomes after treatment. Per the American 
Psychiatric Publishing Textbook of Substance Abuse Treatment (The American 
Psychiatric Association, 2014), ideal treatment after detoxifying from substances is 
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ineffective if it is not continuing at least 6–12 months in duration (Godley et al., 2007; 
Dennis et al., 2007). Since the data collection site for this study functions at one of the 
highest levels of care (rated as hospital level intensity according to ASAM placement 
criteria), the next level of care on an ideal continuum for appropriate step-down would be 
residential treatment (RT). Preferably, residential treatment should then be followed by 
less intensive levels of care (American Society of Addiction Medicine, ASAM). The 
duration and intensity of treatment should be clinically tailored to each individual 
patient’s needs and may vary from a few months to several years (American Psychiatric 
Association, 2010). It is important to point out however, that in real-life treatment choice 
making, the “decisions” of adolescents, while legally theirs alone, are often heavily 
influenced. Parental and collateral expectations, and sometimes even requirements from 
courts and probation officers might have colored the true autonomy of the choice. 
 
Thee ordinal scale was categorized in the following manner:  
 
0. (NC): Patients leaving Against Medical Advice (AMA) or being removed for 
violence or non-compliance represent non-completion of the program.  
1. (UN): Unstructured or No treatment.  
2. (SOP): Standard Outpatient. 
3. (IOP): Intensive Outpatient, Partial Hospitalization treatment. 
4. (RT): Residential Treatment.  
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Research Questions and Analysis  
 The main research questions were as follows:  
 
 Research question 1: Is family history of drug use related to adolescent decisions 
for continuing care choices (CCC)?  
Hypothesis 1: I hypothesized that family history of drug use would be related to 
continuing care choices. 
Research question 2:  Is CLA related to adolescent decisions for continuing care 
choices (CCC)?  
 Hypothesis 2: With CLA oft presenting as a personality type with externalizing, 
anti-social behavioral characteristics, it is hypothesized that it will deter adolescent 
patients from any continuing care that might interfere with getting what they want, when 
they want it. I expected that CLA would be negatively related to aftercare choices such 
that higher levels of CLA would be related to the easiest least restrictive choices possible. 
 To answer research question 1, mean CLA scores and standard deviations were 
calculated. Ordinal regression was used to examine the relationship between CLA scores 
and aftercare choices.  
 Research question 3: Is refusal self-efficacy (RSE) related to adolescent 
decisions for continuing care choices (CCC)?  
 Hypothesis 3: The literature demonstrates the consistent influence of this 
measure; thus, I expected to see a similar pattern in this sample. It was hypothesized that 
a negative relationship would exist between RSE and CCC, such that low RSE scores 
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will relate to continuing care choices of greater structure and intensity.  
 To answer research question 2, mean RSE scores and standard deviations were 
calculated. Ordinal regression was used to examine the relationship between RSE scores 
and aftercare choices.  
 Research question 4: Is social capital (SC) related to adolescent decisions for 
continuing care choices?  
Hypothesis 4: The literature demonstrates that adolescent motivation for sobriety 
is often a result of outside forces and expectations, so it is hypothesized that social capital 
will influence more structured treatment options.  
To answer this question, the mean score and standard deviations for the SC were 
calculated. Using a multiple regression analysis with the dependent variables of the 
ordinal aftercare choices, I determined how the SC appeared to moderate the aftercare 
decisions. The direction, strength of, and equation for the relationship are reported.  
 Research question 5: Are the interactions of the independent variables related to 
adolescent decisions for continuing care choices?  
a. Do SE and SC interact?  
b. Do CLA and SC interact?  
c. Does CLA, and RSE interact?  
Hypothesis 5: I hypothesized that low RSE would be influenced negatively by 
higher negative SC influences, i.e. substance using peers. Inversely, positive SC 
influences will display more moderate to high RSE values, whereas CLA and SC would 
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likely be more associated with higher CLA values and thus correlated with negative SC 
influences, with both very low and very high RSE values.  
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CHAPTER FOUR: RESULTS 
This chapter presents the descriptive analyses of participants included in this 
study, the preliminary analyses run on the data, and the results obtained by the linear 
regression.  
Descriptive Analyses  
Means and standard deviations were computed for each of the three independent 
variables (Table 1): Refusal Self-efficacy (RSE), Common Liability to Addiction (CLA), 
and Social Capital (SC). On a scale of 1 to 7, a mean RSE score of 5.34 (SD=1.84) was 
obtained, indicating a high confidence within the population to resist drugs. On a scale of 
0–25, participant responses indicating the presence of common liability to addiction 
(CLA) phenotypes within the population indicated a mean CLA of 6.9 (SD=5.26). 
Finally, a SC score on a scale of 0 to 48, with a Mean of 35.39 (SD=6.05) was obtained, 
indicating the amount of social resources available to the participants.  
Means and standard deviations were also computed for each continuing care 
choice group (Table 1). For Refusal Self-efficacy, means ranged from a high of 5.78 for 
participants in the standard outpatient treatment group (N=41) to a low of 4.38 for 
participants in the residential treatment group (N=16). The common liability to addiction 
ranged from a high of 10.33 for the participants who in the non-compliant (N=6) group to 
6.29 for those who fell into the standard outpatient group (N=41). Social capital scores 
ranged from a high of 37.5 for those participants who chose non-structured treatment 
outcomes (N=4) to a low of 31.19 for those who opted for the more structured residential 
treatment continuing care choice (N=16).  
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Table 2  
Means and Standard Deviations by Total Group and Treatment Choice Groups 
 TOTAL 0, (N=6) 1, (N=4) 2, (N=41) 3, (N=4) 4, (N=16) 
 M SD M SD M SD M SD M SD M SD 
RSE 5.34 1.84 4.67 2.07 5.50 1.73 5.78 1.24 5.50 1.29 4.38 2.75 
CLA 6.9 5.26 10.33 4.93 6.75 4.50 6.29 5.27 7.75 3.86 7.00 5.82 
SC 35.59 6.05 36.33 6.44 37.5 3.70 36.85 5.61 37.25 3.69 31.19 6.38 
 
These variables were then correlated using Pearson 2-tailed coefficient, which 
demonstrated a significant relationship between RSE and CLA, and RSE and SC (Table 
2). The significance indicated that the higher the CLA, the less efficacious a person felt 
and the higher the SC, the higher the perceived efficacy. There was no significant 
correlation between CLA and SC.  
 
Table 3  
2-tailed Pearson Correlations 
 RSE CLA SC 
RSE __ -.420** .397** 
CLA  __ -.223 
SC   __ 
** Correlation is significant at the 0.01 level (2-tailed). 
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Preliminary Analyses  
Chi-square tests of independence were run to determine if any of the background 
variables were related to participants’ continuing care choices. No significant 
relationships were found between continuing care choices and gender, [X2. (1) =2.498, p< 
.645)], ethnicity [(X2. (1) =6.22, p<.904)], drug of treatment [(X2. (1) =3.53, p<.897)], 
previous treatment attempts [(X2. (1) =2.984, p< .560)], and family history of alcohol 
abuse [(X2. (1) =1.92, p < .750)]. At the same time, two background variables, living 
situation [X2. (1) =39.079, p > .027] and family history of drug use [X2. (1) = 9.56, p > 
.049], were both found to have significant relationships with participants’ continuing care 
choices. However, the variables that made-up living situation displayed common 
similarity in the count and expected count, allowing us to combine the variables. Living 
Situation #2 became:  
1. Parents living together,  
2. One parent + Separated shared custody, and  
3. All the other living options: foster care, living with other relative, other, and 18. 
This new category for living situation [X2. (1) =9.845, p< .276)] no longer displayed any 
significant interaction with continuing care outcome choices.  
Main Analyses  
To determine the relationship between the independent variables of refusal self-
efficacy, common liability to addiction, and social capital, and the dependent variable of 
continuing care choices, ordinal regression was employed.  
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While family history of drug use was not included in my original hypothesis, 
preliminary analyses indicated its relevance, therefore it was included in the main study 
analyses. Thus, research questions included the following five questions:  
 Research question 1: Is FHxD related to adolescent decisions for continuing care 
choices? 
 Research question 2: Is CLA related to adolescent decisions for continuing care 
choices? 
 Research question 3: Is refusal self-efficacy (RSE) related to adolescent 
decisions for continuing care choices? 
 Research question 4: Is social capital (SC) related to adolescent decisions for 
continuing care choices?  
 Research question 5: Are the interactions of the independent variables related to 
the dependent variable of adolescent decisions for continuing care choices?  
Using information from the descriptors I began with the family history of drug 
use to ascertain how much of the variance could be described by that variable alone. 
However, before looking at the effects of each explanatory variable in the model, I 
determined whether the model improves the ability to predict the outcome. This was done 
by comparing a model without any explanatory variables (the baseline or Intercept Only 
model) against the model with all the explanatory variables in the “Final” model. (This 
will eventually have several explanatory variables, as seen in the degrees of freedom “df” 
although at the moment it only contains family history of drug use).  
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Table 4  
Continuing Care choices by family history of drug use: Model Fitting Information 
Model Log Likelihood Chi-
Square 
df Sig. 
     
Intercept Only 28.847    
Final 27.248 1.240 1 .266 
 
 Based on Table 4, the difference between the two log-likelihoods—the chi 
square—has an observed significance level of greater than 0.05. This means that I cannot 
reject the null hypothesis that the model without predictors is as good as the model with 
predictors, making the model using only family history of drug use a poor model.  
In ordinal regression, the pseudo R square informs the percent of variance that the 
model explains. As some of the most commonly used descriptors are the Cox and Snell 
and the Nagelkerke (Harbaugh, 2017), this dissertation will use these to determine the 
approximate proportion of variance. This model’s Pseudo R-Square appeared to be a poor 
fit explaining only between 1.7 and 1.9 percent of the variance in outcome choices.  
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Table 5  
Model 1: Continuing Care choices by family history of drug use 
Variable Parameter Estimate Standard Error P-value 
    
CCC = 0 -2.57 .467 .000 
CCC = 1 -1.99 .387 .000 
CCC = 2  .796 .291 .006 
CCC = 3 1.096 .308 .000 
FHxD -.590 .532 .267 
 
 This model (Table 5) demonstrates that FHxD is in fact not a significant predictor 
of continuing care choices. Thus, the next step was to examine CLA and determine if 
CLA was a significant predictor of treatment outcome choices.  
 
Table 6  
Continuing Care choices by Common Liability to Addiction: Model Fitting Information 
Model Log Likelihood Chi-Square df Sig. 
     
Intercept Only 99.95    
Final 99.66 .289 1 .591 
 
 Based on Table 6, the chi square also has an observed significance level of greater 
than 0.05 at .591. This means that I cannot reject the null hypothesis that the model 
without predictors is as good as the model with predictors, making this a poor model.  
This model’s Pseudo R-Square also demonstrated a poor fit explaining .4 percent 
of the variance in outcome choices. 
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Table 7 
Model 2: Continuing Care choices by Common Liability to Addiction 
 
Variable Parameter Estimate Standard Error P-
value 
CCC = 0 -2.550 .536 .000 
CCC = 1 -1.972 .469 .000 
CCC = 2  .778 .397 .050 
CCC = 3 1.076 .409 .009 
CLASum -.024 .044 .586 
 
This model (Table 7) demonstrates that CLA is also not a significant predictor of 
continuing care choices. However, recognizing that factors in combination may explain 
variance that may not be observable in isolation, I ran the model with both FHxD and 
CLA.  
So, for my next model, I ran continuing care choices with family history of drug use by 
the common liability to drug use, to see if that was significant or insignificant.  
 Based on Table 8, I saw that the chi square also has an observed significance level 
of .441 which is greater than 0.05. This means that I cannot reject the null hypothesis that 
the model without predictors is as good as the model with these two predictors, making 
this a poor model. This model’s Pseudo R-Square also demonstrated a poor fit explaining 
only between 2.3 and 2.5 percent of the variance in outcome choices.   
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Table 8  
Continuing Care choices with Family history of drug use by Common Liability to 
Addiction: Model Fitting Information 
Model Log Likelihood Chi-
Square 
df Sig. 
     
Intercept Only 119.16    
Final 117.5 1.6 2 .441 
 
Table 9  
Continuing Care choices with Family history of drug use by Common Liability to 
Addiction: Model Fitting Information 
Variable Parameter Estimate Standard Error P-value 
CCC = 0 -2.779 .575 .000 
CCC = 1 -2.190 .511 .000 
CCC = 2  .604 .421 .151 
CCC = 3 .902 .431 .036 
    
CLASum -.029 .045 .520 
FHxD -.620 .534 .245 
 
This model (Table 9) demonstrates that the P-values of CLA in combination with FHxD 
are still not a significant predictor of the variance in outcome choices.  
The next question was to examine if refusal self-efficacy and social capital 
influence treatment choices. So, I ran the model with both RSESum and SCSum.  
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Table 10  
Continuing Care choices by Refusal self-efficacy and social capital: Model Fitting 
Information 
 
Model Log Likelihood Chi-
Square 
df Sig. 
     
Intercept Only 157.868    
Final 139.782 18.09 3 .000 
 
This model appears to be highly significant (Table 10); the chi square has an observed 
significance level of less than 0.05. This means that I can reject the null hypothesis that 
the model without predictors is as good as the model with predictors, making this an 
acceptable model. Accordingly, with refusal self-efficacy and social capital sums, the R-
Square accounts for between 23–25% of the variance in outcome choices.  
Table 11  
Model 4: Continuing Care choices by Refusal self-efficacy and social capital 
Variable Parameter Estimate Standard Error P-value 
CCC = 0 -25.665 7.655 .001 
CCC = 1 -25.052 7.637 .001 
CCC = 2  -21.911 7.516 .004 
CCC = 3 -21.514 7.502 .004 
    
RSESum -3.210 1.193 .007 
SCSum -.681 .223 .002 
RSESum*SCSum .096 .035 .006 
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In order to understand the interactions and the ways the different models might 
explain adolescent choices, it seemed logical to again run this model with FHxD to 
determine if this may have an effect.  
 
Table 12  
Continuing Care choices by Family history of drug use with Refusal self-efficacy and 
social capital: Model Fitting Information 
Model Log Likelihood Chi-Square df Sig. 
     
Intercept Only 164.224    
Final 144.857 19.367 4 .001 
 
This model appears to be highly significant (Table 12); the chi square has an 
observed significance level of less than 0.05. This means that I can reject the null 
hypothesis that the model without predictors is as good as the model with predictors, 
making this an even better model. Consequently, for family history of drug use with 
refusal self-efficacy and social capital sums, the R-Square accounts for between 24–26% 
of the proportion of variance in outcome choices. Thus, this model accounts for even 
more of the variance then the model without FHxD, accounting for 24–26% of the 
variance in continuing care choices.  
In order to understand the interactions and the ways the different models might 
explain adolescent choices, it seemed logical to again run this model with additional 
factors of FHxD and Common Liability to Addiction sum to determine if this may have 
an effect.  
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The model in Table 13 shows that I can reject the null hypothesis that the model 
without predictors is as good as the model with predictors, making this an even better 
model. Consequently, when Family history of drug use is considered with common 
liability to addiction, refusal self-efficacy, and social capital sums, the R-Square accounts 
for between 24–26% of the proportion of variance in outcome for continuing care choices 
of adolescents.  
 
Table 13  
Model 5: Continuing Care choices by Family history of drug use with Refusal self-
efficacy and social capital 
Variable Parameter Estimate Standard Error P-value 
CCC = 0 -26.293 7.828 .001 
CCC = 1 -25.655 7.808 .001 
CCC = 2  -22.467 7.686 .003 
CCC = 3 -22.068 7.672 .004 
    
FHxD -.665 .594 .263 
RSESum -3.363 1.221 .006 
SCSum -.696 .228 .002 
RSESum*SCSum .101 .036 .005 
    
 
As I can see in model 5, RSESum, SCSum, and the interactions between the two 
all continue to be significant predictors of variance for continuing care choices. However, 
adding the influence of FHxD in model 5 has increased the power of the other variables 
and the direction of movement towards the choices that the adolescents make. Logically, 
this led me to run a full model to see if adding the additional variables and interactions 
might likewise have an even greater influence.  
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In order to do this, I ran FHxD, CLA, RSE, and SC with all the subsequent 
interactions.  
Table 14  
Continuing Care choices by Family history of drug use with Common Liability to 
addiction sum, Refusal self-efficacy, and social capital: Model Fitting Information 
 
Model Log Likelihood Chi-
Square 
df Sig. 
     
Intercept Only 168.4    
Final 145.6 22.805 7 .002 
 
This model appears to be the most significant (Table 13); the chi square still has 
an observed significance level of less than 0.05 at .002. This model shows the greatest 
significance with 28%–30% of the variance in continuing care choices being accounted 
for in this model. In combination, FHxD and CLA added with RSESum, SCSum, and all 
the interactions within the model, influenced outcome choices.  
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Table 15 
Model 6: Continuing Care choices by Family history of drug use with Common Liability 
to addiction sum, Refusal self-efficacy, and social capital  
 
Variable Parameter Estimate Standard Error P-value 
CCC = 0 -33.136 9.927 .001 
CCC = 1 -32.493 9.906 .001 
CCC = 2  -29.184 9.758 .003 
CCC = 3 -28.776 9.743 .003 
    
FHxD -.6888 .602 .253 
CLASum -.389 .362 .282 
RSESum -4.260 1.427 .003 
SCSum -.828 .273 .002 
CLASum*RSESum .033 .029 .268 
CLASum*SCSum .004 .010 .662 
RSESum*SCSum .118 .039 .003 
    
 
Similar to model 4, adding in the additional variables gives much more nuanced 
explanations for models 5 and 6. When accounting for FHxD and CLA I can see the 
influence on RSE and SC, as well as the interactions increasing the power and direction 
of the choices.  
According to the analysis, it appears that RSESum, SCSum are both significant 
predictors. For RSESum the direction is negative so that for each one unit increase in 
RSE, there is a 4.3-unit decrease in the ordered log odds of choosing a higher level of 
treatment. For SCSum, the direction is negative so that for every unit increase in the 
ordered log odds of SCSum, there is a .828 decrease of choosing a higher level of further 
treatment. In addition, it appears that the interaction RSESum and SCSum is also 
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influential on outcome choices. However, this statistically significant interaction between 
RSESum * SCSum is positive. This indicates that for every increase by one unit in the 
RSESum*SCSum, it would be expected to have a .12 move in the direction of further 
treatment.  
Thus, a model 6 for predicting continuing care choices would be depicted by the 
equation: 
y=0.688 FHxD-4.26 RSESum-0.828SCSum+0.118RSESum*SCSum 
 
from this I can then calculate the latent variables for each subject, comparing to 
the cut-offs:  
 
CCC=0 if y < -33.1 
CCC=1 if -33.1 < y < -32.5 
CCC=2 if -32.5 <y < -29.2 
CCC=3if -29.2 < y < -28.8 
CCC=4 if y > -28.8 
Summary  
 For research question one, is family history of drug use related to adolescent 
continuing care choices, while an influencing factor in combination with other variables, 
family history of drug use does not, on its own, influence continuing care choices.  
 For research question two, is CLA related to adolescent continuing care choices, I 
found that CLA is also not on its own related to continuing care choices.  
For research question three, is RSE related to adolescent continuing care choices, I found 
that RSE does relate to adolescent decisions as lower refusal self-efficacy encouraged 
more dependence on higher structured treatment options, and higher refusal self-efficacy 
participants opted for less structured methods of treatment.  
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 For research question four, is SC related to adolescent continuing care choices, I 
determined SC to be related to adolescent decisions for aftercare with the model showing 
those with higher SC choosing less structured forms of treatment.  
 For research question five, are the interactions between the independent variables 
related to adolescent decisions for continuing care choices, I found interactions between 
the different variables, RSESum, CLASum, and SCSum. These interactions indicated that 
while FHxD and CLA was non-significant in combination with RSESum and SCSum, 
there was an influence on continuing care choices, producing more significant 
interactions. As SC increased so did RSE. SC also had a negative interaction showing a 
decrease in treatment levels correlating with increases in social capital and refusal self-
efficacy, and increases in refusal self-efficacy corresponding with higher levels of social 
capital.  
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CHAPTER FIVE: DISCUSSION 
This dissertation examined the influence of adolescent refusal self-efficacy, social 
capital, and the common liability to addiction on continuing care choices. Evidence was 
found to support the influence of refusal self-efficacy and social capital on these 
outcomes. Following the results of the preliminary analyses, family history of drug use 
was included in the list of predictor variables examined, in relation to the outcome of 
adolescent continuing care choices. In the following sections, the results obtained will be 
discussed and explored within the context of our existing knowledge base regarding 
adolescent addiction treatment.  
Summary of Findings  
The Relevance of the Independent Variables  
The present study determined that family history of drug use and the common 
liability to addiction were not related to continuing care choices of adolescents. Refusal 
self-efficacy was negatively related to adolescent continuing care choices, such that 
adolescents with lower refusal self-efficacy beliefs were more likely to choose higher 
structured treatment options, while adolescents with higher refusal self-efficacy beliefs 
were more likely to opt for less structured methods of treatment. I also discovered, to my 
surprise, that social capital was inversely related to adolescent continuing care choices, 
demonstrating that those with higher social capital chose less structured forms of 
treatment. I also found significant interactions between the different variables, refusal 
self-efficacy (RSE), and social capital (SC). Family history of drug use (FHxD) and the 
common liability to addiction (CLA) were both non-significant predictors of adolescents’ 
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continuing care choices; however, in combination with RSE and SC, I observed a small 
increase in the variance accounted for in adolescents’ choices.  
Family History of Drug Use  
My original research questions did not include family history of drug use (FHxD) 
as a predictor of continuing care choices. It was however added to the list of research 
questions, following a preliminary analysis that indicated a significant relationship with 
the outcome variable. I found that even though initial chi-square analyses indicated a 
significant relationship between FHxD and adolescent continuing care choices, this 
relationship was no longer significant when added to the ordinal regression. Nevertheless, 
when FHxD was added to the ordinal regression along with RSE and SC, it increased the 
variance in outcomes accounted for by 2%. It remained, however, a non-significant 
predictor of outcomes, thus making it difficult to understand the importance of the 
additional 2% of the variance accounted for. It may be that the preliminary analyses 
resulted in the identification of a spurious relationship between these variables. In this 
case, our initial Chi-Square analysis falsely indicated a relationship through the presence 
of some third or yet unseen variable, which implied a connection that ultimately turned 
out not to be causal (Vogt, 2007). The increase in variance is an interesting finding; 
future studies should include larger sample sizes to expound on this.  
The failure of FHxD as a predictor of continuing care choices could be 
understood as a lack of insight and logical decision-making by adolescents. It is known 
that even though adolescents are cognitively capable of self-reflection and logical 
deliberation, they often display limited levels of insight and display high levels of 
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impulsive decision-making (Abadi, 2011; Casey & Jones, 2010), making it 
understandable that they might not make the best decisions regarding treatment, 
regardless of family history or evidence that they might need additional help. In fact, an 
unsurprising finding of a 2012 qualitative study looking at youth opinions on relapse and 
the chronicity of drug abuse (Gonzalez, 2012) found that most youth downplay the 
importance of treatment, and instead regard recovery as a matter of changing behaviors, 
improving will-power, and making better choices; sometimes regardless of evidence of 
extensive family substance abuse.  
Common Liability to Addiction  
My initial hypothesis about the nature of the common liability to addiction was 
that these variables would produce a natural resistance, steering them away from 
treatment, and would thus be a negative predictor of the intensity of continuing care 
choices made. However, this hypothesis was unsupported as CLA showed no significant 
influence on continuing care choices. This was surprising given that we know addiction 
and common liability traits run in families; and the family dynamic includes patterns of 
behavior which can be embedded in developmental growth of youth, producing certain 
personality characteristics (Hser, Longshore, & Anglin, 2007; Karmiloff-Smith et al., 
2014; Vanyukov et al., 2000; Sampson & Laub, 2005; Tarantino et al., 2014; Tarter, 
2004).  
Such a finding speaks to the complexity of the CLA and addiction in general. 
While addictive disorders have long been associated with anti-social behavior and 
disinhibited personality traits such as impulsivity, sensation-seeking, rebelliousness, and 
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aggression (Krueger, 1999; Krueger et al., 2002; Krueger & Markon, 2006), the spectrum 
of characteristics employed in the CLA is broader than in the scales measuring such 
externalizing traits (Kirisci et al., 2012). Whereas addiction risk is phenotypically and 
genetically correlated with disinhibition and externalizing behaviors in childhood (Elkins, 
McGue, & Iacono, 2007; Grove et al., 1990; Krueger et al., 2002; Iacono et al., 2008), 
many additional psychological characteristics in the CLA such as depression and 
impulsivity, are also related to risk for addiction (Bechara, 2005; Elkins, King, McGue, & 
Iacono, 2006; Giancola et al., 1996; Spear, 2000). In this study it is unknown as to how 
effects of trauma or other influences may have influenced the low connection of CLA or 
what other additional factors may have acted to affect these results. 
In this study it is unknown as to how effects of trauma or other influences may 
have been factors associated with risk of addiction, as this information was not in the 
dataset. While research with smaller clinical samples of youth shows strong associations 
between trauma and substance abuse (Chasser, 2016), a recent meta-analysis suggests a 
modest positive relationship between trauma exposure and subsequent addiction patterns, 
that is more apparent in studies of outcomes associated with childhood trauma that are 
best identified through longitudinal methods (Thege, Horwood, Slater, Tan, Hodgins, & 
Wild, 2017). Thus, future studies that include measures of trauma exposure may further 
help to identify the unique contribution of CLA. 
Further, the process of the choices adolescents make in treatment is also 
incredibly complex (Belendiuk, 2014), with a plethora of other influences including 
family pressure, legal pressure, varying levels of developmental growth, and even peers 
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(Kirillova et al., 2008). While, the common liability to addiction is predictive of 
ultimately developing addiction (Kirisci et al., 2013; Kirisci et al., 2012; Vanyukov et al., 
2003a), its predictive value did not extend to the individual choices of adolescents.  
Refusal Self-Efficacy  
I hypothesized that refusal self-efficacy would be related to adolescent continuing 
care choices, and I found this to be supported. The data showed that refusal self-efficacy 
is significantly related to adolescent decisions, such that adolescents with lower refusal 
self-efficacy scores were more likely to choose more highly structured treatment options, 
while those with higher refusal self-efficacy scores were more likely to opt for less 
structured methods of treatment. This was, in fact, in line with expectations and is well 
supported by the literature (Bandura, 1999; Burleson & Kaminer, 2005; Schell et al., 
2005; Walker et al., 2011). Bandura (1999) found that people with high perceived self-
efficacy view relapses as minor slips and redouble efforts to assume control, whereas 
those with low self-efficacy will feel that they need additional help because they cannot 
control it on their own. Our study also showed that high drug refusal self-efficacy was 
associated with continuing care choices for lower levels of care, demonstrating that the 
youth in my sample held similar beliefs to Bandura’s suggestion. Burleson and Kaminer 
(2005) showed that improving refusal self-efficacy during treatment improved incidences 
of abstinence, and that those youth with low refusal self-efficacy may be more 
susceptible to the lure of positive emotional temptations to return to substance use.  
My study also demonstrated that lower refusal self-efficacy beliefs were related to 
decisions for higher, more structured, and supported levels of care, perhaps because 
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youth believed that in such settings they could better avoid the lure of relapse 
temptations. Schell et al. (2005) likewise found that low refusal self-efficacy to resist 
drugs was associated with higher levels of treatment, and yet preconceived cognitions 
and emotions about treatment would affect those choices, and the vast array of emotions 
adolescent youth experience is likely to influence the decisions about treatment. 
Adolescents are easily aroused, angered, and get passionate about things even in 
treatment. This liability and developmental immaturity tends to incite a desire to leave 
treatment and return to their normal lives; thus, these emotions are still likely to be a 
large and unexplainable factor in choices.  
Social Capital 
As one of the two most frequent factors present when making the change from 
active drug user to abstaining from substances and having a new productive life, 1. first 
having attended formal treatment, and 2. having access to a certain level of social 
connectedness (Hser, Anglin, Grella, Longshore, & Prendergast, 1997; Hser et al., 2007), 
social capital was initially associated with seeking a higher and more secured level of 
treatment. This hypothesis, however, was unsupported. In fact, my study demonstrated 
that youth with higher social capital chose less structured forms of treatment. This finding 
was unexpected given that social capital was initially conceptualized as containing those 
external forces (Battjes et al., 2003) that provide the motivational pressure to encourage 
treatment, and thus, higher and safer levels of care.  
Logically, however, these results could be indicating that adolescents who 
believed they had positive social capital resources also believed that these resources 
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would help them better control their substance use. Such adolescents might see lower 
structured treatment options as adequate for them, given their high level of social capital 
support. Of concern, however, is that similar to refusal self-efficacy, I measured youth’s 
perception of social capital; and life course studies show that initial involvement with 
drugs may result from peer pressure, drug availability, and a combination of risk factors 
in an individual’s environment (Hser, 2009 ). The escalation and maintenance of greater 
drug use are thought to result from contributions of biological, psychological, or 
psychiatric, traits of the individual user (Hser et al., 2007). Thus, perceptions of social 
capital are affected by a plethora of immeasurable factors; and there is no way to 
determine through our results, how and if perceptions and subsequent decisions for 
continuing care choices are influenced by these variables (Schell et al., 2005).  
 These findings speak to the difficulties imposed on substance abuse treatment by 
the challenge of development (Chambers et al., 2003), the difficulty clinicians and youth 
face when attempting to address the influence of peers (Albert, Chein, & Steinberg, 
2013), and the high relapse rates youth suffer despite the demonstrated effectiveness of 
treatment (Brown et al., 1989; Dennis, 2014).  
Interactions between Independent Variables  
 
I correctly hypothesized that Refusal Self-Efficacy would be influenced 
negatively by higher negative Social Capital influences, and that this would influence a 
negative direction for continuing care treatment. Inversely, however, I incorrectly 
expected positive social capital influences to display more choices for higher levels of 
continuing care. I also found CLA to be completely non-significant in relation to 
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outcome. In Model 4 I found that the interaction between refusal self-efficacy and social 
capital was significantly related to adolescents’ decisions for continuing care. The related 
nature of refusal self-efficacy and social capital and youth choices, were not surprising 
given the extensive literature on those variables (Bandura, 1999; Bandura & Locke, 2003; 
Burleson & Kaminer, 2005; DiClemente, 1986). Refusal self-efficacy and social capital 
were both negatively related to continuing care choices, indicating that youth with 
perceptions of high refusal self-efficacy and high social capital resources felt they could 
manage their addiction with lower levels of care. I also found however, that refusal self-
efficacy interacted with social capital to produce a positive relationship with 
progressively higher levels of care, perhaps speaking to the influence of social capital as 
a protective factor (Hser, 2009). These findings seem to be aligned with what Maisto 
(2011) posited; low substance-resistance efficacy decreased periods of abstinence, which 
led to increased substance-related problems (lowering social capital), the ensuing 
problems became a very concrete external force, compelling a form of insight in the 
perceived need for treatment. These results demonstrate that adolescents, despite their 
limited development and ability to contain impulsive choices for immediate pleasure 
(Casey & Jones, 2010) (refusal self-efficacy), often are directed by outside forces (their 
social capital levels), to guide the process of making decisions for more secured treatment 
(Battjes et al., 2003). As varying levels of refusal self-efficacy combined with social 
capital, there was an increase in the amount of youth willing to seek higher levels of care. 
Perhaps this represents more of what I had originally anticipated as “insight” was 
encouraged by family and other environmental influences.  
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In model 5 with the addition of family history of drug use, I discovered greater 
significance of refusal self-efficacy, and social capital, as well as their interaction. 
However, FHxD was still insignificant. In model 6, with the addition of common liability 
to addiction as a variable, I saw even greater variance accounted for and increases in the 
significance of refusal self-efficacy, as well as the interaction of refusal self-efficacy and 
social capital. Social capital remained significantly constant between models 4 and 6 
demonstrating it was related to continuing care choices.  
Of interest, it was determined in this study that the more I included variables such 
as family history of drug use, and common liability to addiction, the more the 
significance of refusal self-efficacy and social capital increased. These interactions 
demonstrated that while FHxD and CLA were non-significant in terms of being related to 
continuing care choices, in combination with RSE and SC, they increased the variance in 
relationship to continuing care choices, perhaps highlighting the complex and dynamic 
nature of addiction and developmental forces, particularly when it comes to the incredible 
variance found among adolescents. It remains unclear, however, how to fully make sense 
of the potential role that family history of drug use and common liability to addiction 
may play in adolescents’ continuing care choices. While the variance accounted for in the 
aftercare choices of adolescents increased from 2 to 4% from model 4 to model 6, I 
cannot account for this increase.  
Because of this uncertainty, the strongest model for identifying factors related to 
adolescent continuing care choices cannot be considered model number 6. Model 4 
would in fact be the model in which I can have the most confidence. Model 4 includes 
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perceptions of refusal self-efficacy beliefs and social capital, thus still recognizing the 
social and cultural influences of family history and developmental interplay. This model 
best recognizes the fact that historical forces shape the social trajectories of family, 
education, and work, and in turn influence individual behavior and precise lines of 
development (Hser et al., 2007). It is known that for example, relocating to a different 
neighborhood, having low social capital, forming a friendship with a substance using 
peer, or the divorce of parents may increase the slope or trajectory leading to initiating, as 
well as maintaining, substance use during adolescence (Tarter, 2014).While the 
complexity allowed by including the variables in model 6 increased the variance 
demonstrated in the model, perhaps more closely reflecting the reality and “messiness” of 
addiction, I cannot tell how they affect treatment or adolescent decisions about that 
treatment.  
Implications  
 My study contributed to the literature on the effects of family history of drug use, 
the common liability to addiction, refusal self-efficacy, and social capital, on the 
decision-making of adolescents during treatment. I determined that, at least among this 
specific group of adolescents, refusal self-efficacy was related to the perception that they 
could utilize lower levels of treatment to control addiction, while maintaining the 
preferred status quo of their lives before the interruption of in-patient substance abuse 
treatment. Social capital also seemed to encourage positive thoughts about the ability to 
maintain life as usual, while encouraging less restrictive treatment methods to address 
issues that had prompted the inpatient stays.  
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While the family history of drug use, and common liability to addiction, 
combined with social capital and refusal self-efficacy seemed to encourage the most 
variance in the results, this is difficult to interpret. What I do know is that given enough 
social capital, refusal self-efficacy increases; recognition of the power of social resources 
occurs and more secured treatment becomes a more viable option for youth. The power 
of the final model number 4 shows that even adolescents, who typically might 
overestimate abilities while underestimating problems, can be moved by the weight of 
these forces—recognizing perhaps that addiction is not something they can defeat on 
their own—thus creating a new willingness to allow more secure help to enter their lives.  
By including the factors of refusal self-efficacy and social capital, to create a 
more robust model, this focuses on how differing influences across individuals’ lives 
create patterns shaped by the broader historical context and social structures (Tarantino et 
al., 2014; Tarter, 2004). This allows for identifying critical moments, the utilization of 
skill sets in the development of trajectories, producing evidence of both direction and 
movement contributing to persistence (Hser et al., 2007), or in this case change during 
treatment.  
Recognizing levels of refusal self-efficacy, and social capital during treatment 
may provide an opportunity for families, service providers, and collateral workers to 
explore what these factors might mean for the future. For example, treatment providers 
should continue making refusal self-efficacy a concrete emphasis of focus. Improving 
confidence and willingness among youth, to make better choices and improve resistance, 
might be accomplished through developmentally appropriate strategies. Further, 
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involving family bonding can bring forth greater social capital resources. Taking the time 
to point out how these factors have influenced current beliefs about sobriety and 
treatment might continue to encourage insight and examine specifically with the 
adolescents the true value treatment may provide. This outside emphasis, added to the 
treatment decision process, might contain the needed “pressure” or “encouragement” to 
look past immediate desires, and explore the long-term benefits in a more pragmatic and 
realistic way.  
Limitations and Future Research  
As with all empirical studies, this study has its limitations that make 
generalizability to other populations tenuous. First, the sample study was limited by the 
data set, and thus the instruments used were confined to those found in the GAIN, which 
were complete self-reports. This was also a sample of convenience utilizing a previously 
collected subset of data made available through the generosity of the Treatment Center, 
and may not be representative of the general population. In addition, in reality while the 
decisions the adolescents make are “legally” their own to make, life is much more 
complicated. Family influence and parental suggestions might be considered mandatory 
requirements for youth, and this could have coerced some of the decisions. There is also 
the issue that some of the participants had been in treatment before. This means that they 
may have taken the GAIN before which may have influenced the way in which they 
answered the questions. Also, the sample size was small (n=71), which further limits the 
extent to which the conclusions can be generalized, and the sample was also not very 
  
122 
ethnically diverse, with a primarily Caucasian base. Future studies should consider a 
larger and more diverse population.  
Common Liability and Family History  
Despite the limitations and the lack of generalizability, the variance found in this 
study does raise some interesting questions that further research should attempt to 
answer. Future studies should increase the sample size and seek to uncover the cause of 
the observed spurious effects observed. With a greater sample size, would the influence 
of family history of drug use in the Chi-Square analysis still exist? If so, what other 
variables might account for this effect? A qualitative component and follow up analysis 
might elucidate other influences. For example, what role did the youth’s awareness of 
family history play in the initial decision to enter treatment? Was the decision to enter 
treatment that of the parents or of the adolescents? The interactions between CLA and 
family history of drug use are interesting. Further studies, with a larger sample size, 
might utilize a qualitative component and seek to discover the thoughts parents and 
patients have on how family history and genetics might dictate or encourage decision-
making for treatment methodologies.  
Refusal Self-Efficacy  
My findings on refusal self-efficacy, while unsurprising, could be bolstered in 
future studies with a more robust instrument. The utilized refusal self-efficacy 
questionnaire, while improved based on the Schell et al. (2005) study, had only seven 
questions. Perhaps the utilization of a qualitative component or family triangulation 
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might add more information to help understand the ways that refusal self-efficacy might 
play a role in the initial decision to enter treatment, the decision to start using in the first 
place, or even the role that refusal self-efficacy perceptions might play in preventing or 
initiating relapse. Schell et al. (2005) pointed out that any observed relationship between 
cognitive predisposing factors and treatment might represent the causal influence of the 
treatment itself, rather than the disorder or beliefs themselves. Therefore, caution must be 
exercised when interpreting results. Future studies might look closer at how other 
variables or influences have affected these refusal self-efficacy beliefs. Additionally, 
looking at how these beliefs change over time, and using a qualitative component to 
understand why youth feel these beliefs are valid, might aid treatment providers, future 
researchers, and the youth themselves. Future studies should follow the adolescents 
through treatment and continuing care as they measure evolving refusal self-efficacy 
beliefs. Without following up on these adolescents I do not know whether the decisions 
in the study were a result of prior experiences, predisposing factors, treatment influences, 
or whether youth were successful given their choices.  
Treatment providers should use this knowledge to help youth make the best 
decision for treatment highlighting Banduras (1999) point—people with high efficacy can 
gain more from additional treatment, and those with low refusal self-efficacy can 
improve and strengthen such efficacy during additional treatment. 
Social Capital  
In addition, the interactions with social capital and family history highlight the 
role of environment on development. Additional studies might more specifically be 
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designed to understand the interactions between the role of family history, turning points, 
and participants’ own understanding of recovery and treatment from a family dynamic 
perspective. Utilizing a study that includes parents, and other collaterals, could provide a 
better understanding of patient history and available resources, providing a greater depth 
of insight. In addition, family history of drug use may be connected to social capital, and 
looking at family relationships with members that have achieved sobriety, or remain 
addicted, might give the study further insight. Follow-up studies, after the participants 
attempt their chosen modality, could reveal the accuracy of social capital beliefs as well 
as refusal self-efficacy beliefs. This might clarify why youth have the views they do 
regarding treatment, and may even help treatment providers and the youth themselves in 
tailoring interventions that might be the most helpful.  
Having used the Global Appraisal of Individual Needs to mine the data for this 
study it is my opinion that there is a great wealth of data to be found within its constructs. 
The GAIN is an incredibly versatile instrument which meets its goal of allowing research 
to touch the lives of clinicians, clients, and collaterals on the front lines. There were some 
limitations to its usefulness and perhaps it is a testimony to how much it provided that I 
kept wishing it could do more. Unfortunately, it is still based on self-report and the utility 
of it as a psychological instrument also limited its scope. The method of delivery allows 
for certain entire sections to be skipped if certain questions are answered positively or 
negatively and I felt this may have perhaps delivered an incomplete picture of the 
individual answering the assessment. The GAIN is however continuously updated and 
tested to maintain its integrity and accuracy and its widespread adoption and continued 
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usefulness for researchers across the country is a testimony to its great value as a tool for 
clinicians and the populations they serve. 
Conclusion  
In this study, it was determined that refusal self-efficacy and social capital were 
related to outcome choices of adolescents during treatment. Furthermore, including the 
independent variables of family history of drug use and common liability to addiction 
provided a more robust display of the directions adolescents moved towards.  
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APPENDICES 
Appendix A: Demographic Questions 
 
What is your age? 
 
1. Age of onset:  
 
2. What is your gender? 
 
3. What is your family status? 
____Single parent 
____Parents  
____Other relative(s) 
____Care of Department of Children and Families (DCF) 
 
4. What is your race/ethnicity?  
____White (not Hispanic)     
____African American/Black    
____Asian/Pacific Islander/Asian-American 
____Latino/Hispanic   
____Bi/Multiracial  
____Other  
 
5. Have you ever been mandated to treatment? ____ 
6. Have you ever had treatment before? 
7. Is there any family history of alcohol use disorder? 
8. Is there any family history of substance use disorder? 
9. Is there any family history of mental health illness? 
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Appendix B: The Common Liability to Addiction Scale 
                                         (Derived from GAIN, Dennis et al., 2004) 
 
In the last 12 months have you had difficulty with or gotten in trouble for: 
1. M3a4. Not followed instructions or not finished your assignments 
2. M3a11. Been unable to stay in a seat where you were supposed to stay 
3. M3a12. Felt restless or felt the need to run around or climb on things 
4. M3a13. Gotten in trouble for being too loud when you were playing or relaxing 
5. M3a15. Talked too much or had others complain that you talked too much 
6. M3a17. Had a hard time waiting for your turn 
7. M3a16. Gave answers before the person finished asking the question 
8. M3a18. Interrupted or joined other people’s conversations or games without 
 being invited 
 
9. M3b9. Broken windows or destroyed other property 
10. M3b10. Taken money or items from a house, building, or car 
11. M3b11. Lied or conned someone to get something you wanted or to avoid having        
 to do something 
 
12. M3b15. Skipped work or school 
13. M4h. Lied often and easily 
14. M4j. Felt bored easily or hated routines 
15. M4k. Often acted before thinking about the trouble you might get into 
16. M4n. Did not like others telling you how to behave 
During the past 12 months, have you… 
17. M4z. Cut, burned, or hurt yourself on purpose? 
  
128 
18. M1a1. Had significant problems with headaches, faintness, dizziness, tingling, 
 numbness, sweating, or hot or cold spells? 
 
19. M1a2. Had trouble sleeping, for example, bad dreams, restless sleeping, or 
 falling asleep during the day? 
 
20. M1a4. Had pain or felt heaviness in your heart, chest, lower back, arms, legs, or 
 other muscles? 
 
21. M2. f. Felt like you could not go on? 
22. M1c2. Thought about ending your life or committing suicide? 
23. M1c3. Had a plan to commit suicide? 
24. M1c5. Attempted to commit suicide? 
  
  
129 
Appendix C: Refusal Self-Efficacy Scale (RSE) 
                      (GAIN, Dennis et al. 2003; adapted and used by Schell et al. 2005) 
 
S8. Do you currently think you:… 
S8k. Spend a lot of time thinking about alcohol or drugs? 
S8m. Could avoid using alcohol or drugs at home? 
S8n. Could avoid using alcohol or drugs at work or school? 
S8p. Could avoid using alcohol or drugs with your friends? 
S8q. Could avoid using alcohol or drugs when people around you were using them? 
S8c. Will find it hard to resist drugs where you currently live, work, or go to school?  
S8d. Will be pressured by your old friends to drink or use drugs again? 
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Appendix D: Social Capital Scale (SC) 
(GAIN, Dennis et al. 2003) 
 
E5. Of the people, you have regularly lived with, would you say that none, a few, some, 
 most, or all of them… 
 
E5b. Were involved in illegal activity? 
E5e. Shout, argue, and fight most weeks? 
E5f. Have ever been in drug or alcohol treatment? 
E5g. Would describe themselves as being in recovery? 
 
E6. Of the people you have regularly worked or gone to school with, would you say that 
 none, a few, some, most, or all of them… 
 
E6b. Were involved in illegal activity? 
E6e. Shout, argue, and fight most weeks? 
E6f. Have ever been in drug or alcohol treatment? 
E6g. Would describe themselves as being in recovery? 
 
E7. Of the people you have regularly socialized with, would you say that none, a few, 
 some, most, or all of them… 
 
E7b. Were involved in illegal activity? 
E7e. Shout, argue, and fight most weeks? 
E7f. Have ever been in drug or alcohol treatment? 
E7g. Would describe themselves as being in recovery? 
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Appendix D: Site Recruitment Letter and Response 
March 10, 2015 
 
To the Medical Director of CASTLE, 
 
 My name is Erich Engelhardt and I am a Doctoral candidate at Boston University.  
I am conducting research on the relationships between Self-Efficacy and social capital of 
adolescents to see if these psychological and social resources might influence the genetic-
behavioral characteristics of addiction, and affect decisions about continuing aftercare 
treatment. 
Some benefits are the study may possibly reveal what type of influences promote and 
support the long-term management of abstinence and recovery, as well as what type of 
client is influenced by what type of factors. This could possibly assist your agency to an 
even greater degree in tailoring treatments for clients. This would help not only clients, 
but families, and the communities you serve. Based on your reputation for providing 
excellent treatment in your substance abuse programs, I would like to include you in this 
study. If you agree, all I will need from you is the data from the 2011–12 Global 
Appraisal of Individual Needs (GAIN) as well as the selected aftercare choices. 
Clients will be those who were in treatment during the period when CASTLE participated 
in the GAIN Assessment Building System (ABS) so that the data set is accessible, and 
HIPPAA compliant. As far as meeting federal guidelines, all data will of course be de-
identified in accordance with federal security requirements (42 CFR & 2.16); and ii) will 
not be re-disclosed.  
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Thank you for your time and consideration. I hope that you decide to participate in this 
research. If you do, please contact me at your earliest convenience. 
 
Sincerely, 
 
Erich Engelhardt MA, CADC, LADC II 
Ed.D. candidate 
Boston University 
Home:  781-837-3230 
Cell:  530-521-5396 
Erich6474@gmail.com 
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Appendix E: Project Approval  
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